Represent

Lobbying
Lobbying by National Community Pharmacists Association

Lobbying Relationship

Client

National Community Pharmacists Association

More records

Lobbying firm

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION

More records

S. 2666, the E-Prescribing Parity for Controlled Substances Act Remote Prescribing of Controlled Substances
H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024
H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act" (Docket No. FDA-2023-N-4806); Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024; H.R.2882, the Further Consolidated Appropriations Act, 2024;
H.R. 4794, the Dietary Supplement Access Act
S. 127, the PBM Transparency Act; S. 113, the Prescription Pricing for the People Act;
TRICARE pharmacy network changes; H.R. 2670, National Defense Authorization Act for Fiscal Year 2024;
FY24 appropriations language request to fund FTC enforcement of the Robinson-Patman Act; FY24 appropriations report language to address TRICARE pharmacy network;

Duration: January 1, 2008 to present

General Issues: Alcohol & Drug Abuse, Medicare/Medicaid, Pharmacy, Taxation/Internal Revenue Code, Labor Issues/Antitrust/Workplace, Defense, Budget/Appropriations, Small Business, Animals, Health Issues, Insurance, Roads/Highway, Trade (Domestic & Foreign), Veterans

Spending: about $22,449,182 (But it's complicated. Here's why.)

Agencies lobbied since 2008: House of Representatives, U.S. Senate, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS), Drug Enforcement Administration (DEA), Small Business Administration (SBA), White House Office, Centers For Disease Control & Prevention (CDC), Food & Drug Administration (FDA), Treasury - Dept of, Internal Revenue Service (IRS), Federal Trade Commission (FTC), Defense - Dept of (DOD), Health Resources & Services Administration (HRSA), Justice - Dept of (DOJ), Occupational Safety & Health Administration (OSHA), Federal Reserve System, Office of Natl Drug Control Policy (NDCP), Substance Abuse & Mental Health Services Administration (SAMHSA), Office of Management & Budget (OMB), Government Accountability Office (GAO), Medicare Payment Advisory Commission (MedPAC), Labor - Dept of (DOL), Agriculture - Dept of (USDA), Office of Personnel Management (OPM), Environmental Protection Agency (EPA), Natl Economic Council (NEC), Agency for Health Care Policy & Research, Centers For Medicare and Medicaid Services (CMS), Defense - Dept of (DOD), Health & Human Services - Dept of (HHS), U.S. Senate,, Drug Enforcement Administration (DEA),, Congressional Budget Office (CBO), Small Business Adminstration (SBA), Veterans Affairs - Dept of (VA), White House Office,

Bills mentioned

H.R.1854: Prescription Drug Monitoring Act of 2017

Sponsor: Evan Jenkins (R-W.Va.)

S.778: Prescription Drug Monitoring Act of 2017

Sponsor: Amy Klobuchar (D-Minn.)

S.892: Opioid Addiction Prevention Act of 2017

Sponsor: Kirsten E. Gillibrand (D-N.Y.)

H.R.3528: Every Prescription Conveyed Securely Act

Sponsor: Katherine Clark (D-Mass.)

H.R.3545: Overdose Prevention and Patient Safety Act

Sponsor: Tim Murphy (R-Pa.)

S.1850: Protecting Jessica Grubb's Legacy Act

Sponsor: Joe Manchin III (D-W.Va.)

H.R.1271: DXM Abuse Prevention Act of 2017

Sponsor: Bill Johnson (R-Ohio)

H.R.1375: Prescriber Support Act of 2017

Sponsor: Katherine Clark (D-Mass.)

S.523: Budgeting for Opioid Addiction Treatment Act

Sponsor: Joe Manchin III (D-W.Va.)

S.581: Jessie's Law

Sponsor: Joe Manchin III (D-W.Va.)

S.1079: Protecting Americans from Dangerous Opioids Act

Sponsor: Joe Manchin III (D-W.Va.)

H.R.623: Fairness to Pet Owners Act of 2017

Sponsor: Jason Chaffetz (R-Utah)

H.R.1628: American Health Care Act of 2017

Sponsor: Diane Black (R-Tenn.)

H.R.2430: FDA Reauthorization Act of 2017

Sponsor: Greg Walden (R-Ore.)

S.934: FDA Reauthorization Act of 2017

Sponsor: Lamar Alexander (R-Tenn.)

H.R.2810: National Defense Authorization Act for Fiscal Year 2018

Sponsor: William M. Thornberry (R-Texas)

S.1519: National Defense Authorization Act for Fiscal Year 2018

Sponsor: John McCain (R-Ariz.)

S.222: Obamacare Replacement Act

Sponsor: Rand Paul (R-Ky.)

S.469: Affordable and Safe Prescription Drug Importation Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.1245: Affordable and Safe Prescription Drug Importation Act

Sponsor: Elijah E. Cummings (D-Md.)

H.R.1776: Improving Access To Affordable Prescription Drugs Act

Sponsor: Jan Schakowsky (D-Ill.)

S.771: Improving Access To Affordable Prescription Drugs Act

Sponsor: Al Franken (D-Minn.)

H.R.242: Medicare Prescription Drug Price Negotiation Act of 2017

Sponsor: Peter Welch (D-Vt.)

S.41: Medicare Prescription Drug Price Negotiation Act of 2017

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1316: Prescription Drug Price Transparency Act

Sponsor: Doug Collins (R-Ga.)

H.R.1038: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Morgan Griffith (R-Va.)

S.413: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.592: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Brett Guthrie (R-Ky.)

S.109: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.1939: Ensuring Seniors Access to Local Pharmacies Act of 2017

Sponsor: Morgan Griffith (R-Va.)

S.637: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017

Sponsor: Ron Wyden (D-Ore.)

H.R.394: Restoring Access to Medication Act of 2017

Sponsor: Lynn Jenkins (R-Kan.)

S.85: Restoring Access to Medication Act of 2017

Sponsor: Pat Roberts (R-Kan.)

H.R.3921: HEALTHY KIDS Act

Sponsor: Michael C. Burgess (R-Texas)

S.1827: KIDS Act of 2017

Sponsor: Orrin G. Hatch (R-Utah)

H.R.3271: Protecting Access to Diabetes Supplies Act of 2017

Sponsor: Diana DeGette (D-Colo.)

S.870: Creating High-Quality Results and Outcomes Necessary to Improve Chronic...

Sponsor: Orrin G. Hatch (R-Utah)

H.R.421: Allowing Greater Access to Safe and Effective Contraception Act

Sponsor: Mia Love (R-Utah)

H.R.2871: Preserving Patient Access to Compounded Medications Act of 2017

Sponsor: Morgan Griffith (R-Va.)

H.R.749: Lower Drug Costs through Competition Act

Sponsor: Kurt Schrader (D-Ore.)

H.R.631: Death Tax Repeal Act of 2017

Sponsor: Kristi Noem (R-S.D.)

S.205: Death Tax Repeal Act of 2017

Sponsor: John Thune (R-S.D.)

H.R.244: MAC Transparency Act

Sponsor: Doug Collins (R-Ga.)

S.1406: Saving Access to Compounded Medications for Special Needs Patients Act

Sponsor: David Vitter (R-La.)

H.R.471: Ensuring Patient Access and Effective Drug Enforcement Act of 2015

Sponsor: Tom Marino (R-Pa.)

S.483: Ensuring Patient Access and Effective Drug Enforcement Act of 2016

Sponsor: Orrin G. Hatch (R-Utah)

S.524: Comprehensive Addiction and Recovery Act of 2016

Sponsor: Sheldon Whitehouse (D-R.I.)

H.R.953: Comprehensive Addiction and Recovery Act of 2015

Sponsor: F. James Sensenbrenner (R-Wis.)

S.776: Medication Therapy Management Empowerment Act of 2015

Sponsor: Pat Roberts (R-Kan.)

H.R.1021: Protecting the Integrity of Medicare Act of 2015

Sponsor: Kevin Brady (R-Texas)

H.R.1270: Restoring Access to Medication and Improving Health Savings Act of 2016

Sponsor: Lynn Jenkins (R-Kan.)

S.709: Restoring Access to Medication Act of 2015

Sponsor: Pat Roberts (R-Kan.)

H.R.2: Medicare Access and CHIP Reauthorization Act of 2015

Sponsor: Michael C. Burgess (R-Texas)

H.R.793: Ensuring Seniors Access to Local Pharmacies Act of 2015

Sponsor: Morgan Griffith (R-Va.)

S.1190: Ensuring Seniors Access to Local Pharmacies Act of 2015

Sponsor: Shelley Moore Capito (R-W.Va.)

S.314: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.592: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Brett Guthrie (R-Ky.)

H.R.5951: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Morgan Griffith (R-Va.)

S.3308: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.4909: National Defense Authorization Act for Fiscal Year 2017

Sponsor: William M. Thornberry (R-Texas)

S.2943: National Defense Authorization Act for Fiscal Year 2017

Sponsor: John McCain (R-Ariz.)

H.R.6: 21st Century Cures Act

Sponsor: Fred Upton (R-Mich.)

S.1913: Stopping Medication Abuse and Protecting Seniors Act of 2015

Sponsor: Patrick J. Toomey (R-Pa.)

S.1200: Fairness to Pet Owners Act of 2015

Sponsor: Richard Blumenthal (D-Conn.)

H.R.3174: Fairness to Pet Owners Act of 2015

Sponsor: Jason Chaffetz (R-Utah)

H.R.3250: DXM Abuse Prevention Act of 2015

Sponsor: Bill Johnson (R-Ohio)

H.R.1735: National Defense Authorization Act for Fiscal Year 2016

Sponsor: William M. Thornberry (R-Texas)

S.1376: National Defense Authorization Act for Fiscal Year 2016

Sponsor: John McCain (R-Ariz.)

S.790: Economic Freedom Zones Act of 2015

Sponsor: Rand Paul (R-Ky.)

H.RES.173: Providing for consideration of the bill (H.R. 2) to amend title XVIII of...

Sponsor: Michael C. Burgess (R-Texas)

S.810: SGR Repeal and Medicare Provider Payment Modernization Act of 2015

Sponsor: Orrin G. Hatch (R-Utah)

H.R.979: FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act

Sponsor: Stephen F. Lynch (D-Mass.)

H.R.891: Medication Therapy Management Benefits Act of 2011

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.274: Medication Therapy Management Empowerment Act of 2011

Sponsor: Kay Hagan (D-N.C.)

H.R.1041: FIMBA

Sponsor: Glenn Thompson (R-Pa.)

S.1058: Pharmacy Competition and Consumer Choice Act of 2011

Sponsor: Mark Pryor (D-Ark.)

H.R.1971: Pharmacy Competition and Consumer Choice Act of 2011

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.1936: Medicare Access to Diabetes Supplies Act of 2011

Sponsor: Aaron Schock (R-Ill.)

H.R.1946: Preserving Our Hometown Independent Pharmacies Act of 2011

Sponsor: Tom Marino (R-Pa.)

H.R.1409: Quality Health Care Coalition Act of 2011

Sponsor: John Conyers Jr. (D-Mich.)

H.R.1839: Community Pharmacy Fairness Act of 2011

Sponsor: Anthony Weiner (D-N.Y.)

S.1560: Nursing Home Resident Pain Relief Act of 2011

Sponsor: Herb Kohl (D-Wis.)

S.1699: Prescription Drug Cost Reduction Act

Sponsor: Herb Kohl (D-Wis.)

H.R.1540: National Defense Authorization Act for Fiscal Year 2012

Sponsor: Howard P. McKeon (R-Calif.)

S.1253: National Defense Authorization Act for Fiscal Year 2012

Sponsor: Carl Levin (D-Mich.)

H.R.1316: Stop Oxy Abuse Act of 2011

Sponsor: Mary Bono Mack (R-Calif.)

S.507: Prescription Drug Abuse Prevention and Treatment Act of 2011

Sponsor: John D. Rockefeller IV (D-W.Va.)

S.513: Saving Kids From Dangerous Drugs Act of 2011

Sponsor: Dianne Feinstein (D-Calif.)

H.R.2939: Pharmaceutical Stewardship Act of 2011

Sponsor: Louise M. Slaughter (D-N.Y.)

H.R.866: National All Schedules Prescription Electronic Reporting Reauthorization...

Sponsor: Edward Whitfield (R-Ky.)

S.312: Patients' Freedom to Choose Act

Sponsor: Kay Bailey Hutchison (R-Texas)

H.R.605: Patients' Freedom to Choose Act

Sponsor: Erik Paulsen (R-Minn.)

S.1356: Affordable Medicines Utilization Act of 2011

Sponsor: Scott Brown (R-Mass.)

S.296: Preserving Access to Life-Saving Medications Act

Sponsor: Amy Klobuchar (D-Minn.)

S.1867: National Defense Authorization Act for Fiscal Year 2012

Sponsor: Carl Levin (D-Mich.)

S.2002: Online Pharmacy Safety Act

Sponsor: Dianne Feinstein (D-Calif.)

S.1251: Medicare and Medicaid FAST Act

Sponsor: Thomas R. Carper (D-Del.)

S.882: STOP Act

Sponsor: Sherrod Brown (D-Ohio)

S.319: Pharmaceutical Market Access and Drug Safety Act of 2011

Sponsor: Olympia J. Snowe (R-Maine)

S.1002: Safe Doses Act

Sponsor: Charles E. Schumer (D-N.Y.)

H.R.1285: To amend the Controlled Substances Act to make any substance containing...

Sponsor: Vern Buchanan (R-Fla.)

S.621: Safe Prescribing Act of 2013

Sponsor: Joe Manchin III (D-W.Va.)

H.R.1024: Medication Therapy Management Empowerment Act of 2013

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.557: Medication Therapy Management Empowerment Act of 2013

Sponsor: Kay Hagan (D-N.C.)

H.R.1188: Preserving Our Hometown Independent Pharmacies Act of 2013

Sponsor: Tom Marino (R-Pa.)

H.R.4709: Ensuring Patient Access and Effective Drug Enforcement Act of 2014

Sponsor: Tom Marino (R-Pa.)

S.2862: Regulatory Transparency, Patient Access, and Effective Drug Enforcement...

Sponsor: Orrin G. Hatch (R-Utah)

H.R.4190: To amend title XVIII of the Social Security Act to provide for coverage...

Sponsor: Brett Guthrie (R-Ky.)

H.R.4577: Ensuring Seniors Access to Local Pharmacies Act of 2014

Sponsor: Morgan Griffith (R-Va.)

H.R.4437: Generic Drug Pricing Fairness Act

Sponsor: Doug Collins (R-Ga.)

S.1493: Medicare Efficient Drug Dispensing Act of 2013

Sponsor: Benjamin L. Cardin (D-Md.)

H.R.83: Consolidated and Further Continuing Appropriations Act, 2015

Sponsor: Donna M.C. Christensen (D-Virgin Islands)

S.2410: Carl Levin National Defense Authorization Act for Fiscal Year 2015

Sponsor: Carl Levin (D-Mich.)

H.CON.RES.25: Establishing the budget for the United States Government for fiscal year...

Sponsor: Paul D. Ryan (R-Wis.)

S.CON.RES.8: An original concurrent resolution setting forth the congressional budget...

Sponsor: Patty Murray (D-Wash.)

S.644: PACT Act

Sponsor: Bob Casey (D-Pa.)

H.R.2845: Diabetic Testing Supply Access Act of 2013

Sponsor: Peter Welch (D-Vt.)

S.1935: Diabetic Testing Supply Access Act of 2014

Sponsor: John Thune (R-S.D.)

S.867: Medicare Prescription Drug Program Integrity and Transparency Act of 2013

Sponsor: Mark Pryor (D-Ark.)

H.R.4069: Ensuring Patient Access and Effective Drug Enforcement Act of 2013

Sponsor: Tom Marino (R-Pa.)

H.R.2375: Transparency and Accountability in Medicare Bidding Act of 2013

Sponsor: Glenn Thompson (R-Pa.)

S.959: Pharmaceutical Quality, Security, and Accountability Act

Sponsor: Tom Harkin (D-Iowa)

S.957: Drug Supply Chain Security Act

Sponsor: Michael Bennet (D-Colo.)

H.R.1919: Safeguarding America's Pharmaceuticals Act of 2013

Sponsor: Robert E. Latta (R-Ohio)

H.R.3089: Compounding Clarity Act of 2013

Sponsor: Morgan Griffith (R-Va.)

H.R.3204: Drug Quality and Security Act

Sponsor: Fred Upton (R-Mich.)

H.R.8:

Sponsor: John A. Boehner (R-Ohio)

H.R.4095: Online Pharmacy Safety Act

Sponsor: Bill Cassidy (R-La.)

H.R.4215: Medicare Pharmacy Transparency and Fair Auditing Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.3376: PACT Act

Sponsor: Bob Casey (D-Pa.)

S.2467: National Defense Authorization Act for Fiscal Year 2013

Sponsor: Carl Levin (D-Mich.)

S.3254: National Defense Authorization Act for Fiscal Year 2013

Sponsor: Carl Levin (D-Mich.)

H.R.4310: National Defense Authorization Act for Fiscal Year 2013

Sponsor: Howard P. McKeon (R-Calif.)

S.3604: Improving Dementia Care Treatment for Older Adults Act of 2012

Sponsor: Herb Kohl (D-Wis.)

H.R.2245: Preserving Access to Life-Saving Medications Act of 2011

Sponsor: Diana DeGette (D-Colo.)

H.R.1204: Community Pharmacy Fairness Act of 2009

Sponsor: Anthony Weiner (D-N.Y.)

S.2191: A bill to extend the temporary suspension of duty on certain rayon...

Sponsor: Susan Collins (R-Maine)

H.R.4489: FEHBP Prescription Drug Integrity, Transparency, and Cost Savings Act

Sponsor: Stephen F. Lynch (D-Mass.)

H.R.5234: PBM Audit Reform and Transparency Act of 2010

Sponsor: Anthony Weiner (D-N.Y.)

H.R.6331: Generating Antibiotic Incentives Now Act of 2010

Sponsor: Phil Gingrey (R-Ga.)

H.R.5235: Medicare Access to Diabetes Supplies Act

Sponsor: Peter Welch (D-Vt.)

H.R.3790: To amend title XVIII of the Social Security Act to repeal the Medicare...

Sponsor: Kendrick B. Meek (D-Fla.)

H.R.4213: Unemployment Compensation Extension Act of 2010

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.5839: To amend the Internal Revenue Code of 1986 to clarify the types of...

Sponsor: Martin Heinrich (D-N.M.)

H.R.5136: National Defense Authorization Act for Fiscal Year 2011

Sponsor: Ike Skelton (D-Mo.)

S.3454: National Defense Authorization Act for Fiscal Year 2011

Sponsor: Carl Levin (D-Mich.)

H.R.3108: Medication Therapy Management Benefits Act of 2009

Sponsor: Mike Ross (D-Ark.)

S.3543: Medication Therapy Management Expanded Benefits Act of 2010

Sponsor: Kay Hagan (D-N.C.)

H.R.2923: Combat Methamphetamine Enhancement Act of 2010

Sponsor: Bart Gordon (D-Tenn.)

S.1383: Dextromethorphan Abuse Reduction Act of 2009

Sponsor: Richard J. Durbin (D-Ill.)

H.R.3763: To amend the Fair Credit Reporting Act to provide for an exclusion from...

Sponsor: John Adler (D-N.J.)

S.3416: A bill to amend the Fair Credit Reporting Act to provide for an...

Sponsor: John Thune (R-S.D.)

H.R.5141: Small Business Paperwork Mandate Elimination Act

Sponsor: Dan Lungren (R-Calif.)

S.3578: Small Business Paperwork Mandate Elimination Act

Sponsor: Mike Johanns (R-Neb.)

H.R.4173: Dodd-Frank Wall Street Reform and Consumer Protection Act

Sponsor: Barney Frank (D-Mass.)

S.3217: Restoring American Financial Stability Act of 2010

Sponsor: Christopher J. Dodd (D-Conn.)

H.R.4: Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy...

Sponsor: Dan Lungren (R-Calif.)

S.782: Economic Development Revitalization Act of 2011

Sponsor: Barbara Boxer (D-Calif.)

H.R.5839: Disaster Savings and Resilient Construction Act of 2012

Sponsor: Geoff Davis (R-Ky.)

H.R.5234: To suspend temporarily the duty on Bayhydur XP 2547.

Sponsor: Tim Murphy (R-Pa.)

H.R.5235: To suspend temporarily the duty on Bayhydur BL 5335.

Sponsor: Tim Murphy (R-Pa.)

S.18: Small Business Paperwork Mandate Elimination Act

Sponsor: Mike Johanns (R-Neb.)

S.72: Small Business Paperwork Mandate Elimination Act of 2011

Sponsor: Max Baucus (D-Mont.)

H.R.4853: Tax Relief, Unemployment Insurance Reauthorization, and Job Creation Act...

Sponsor: James L. Oberstar (D-Minn.)

H.R.6523: Ike Skelton National Defense Authorization Act for Fiscal Year 2011

Sponsor: Ike Skelton (D-Mo.)

H.R.1586: FAA Air Transportation Modernization and Safety Improvement Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.5710: National All Schedules Prescription Electronic Reporting Reauthorization...

Sponsor: Edward Whitfield (R-Ky.)

H.R.5809: Diesel Emissions Reduction Act of 2010

Sponsor: Jay Inslee (D-Wash.)

S.3397: Secure and Responsible Drug Disposal Act of 2010

Sponsor: Amy Klobuchar (D-Minn.)

H.R.5297: Small Business Jobs Act of 2010

Sponsor: Barney Frank (D-Mass.)

S.2161: A bill to suspend temporarily the duty on ion exchange resin,...

Sponsor: Arlen Specter (D-Pa.)

H.R.616: To amend part B of title XVIII of the Social Security Act to provide for...

Sponsor: Marion Berry (D-Ark.)

S.511: Access to Durable Medical Equipment Act

Sponsor: Sam Brownback (R-Kan.)

H.R.1970: Preserve Patient Access to Reputable DMEPOS Providers Act of 2009

Sponsor: Zack Space (D-Ohio)

S.956: Preserve Patient Access to Reputable DMEPOS Providers Act of 2009

Sponsor: Jon Tester (D-Mont.)

H.R.1: American Recovery and Reinvestment Act of 2009

Sponsor: David R. Obey (D-Wis.)

H.R.1427: Promoting Innovation and Access to Life-Saving Medicine Act

Sponsor: Henry A. Waxman (D-Calif.)

H.R.2647: National Defense Authorization Act for Fiscal Year 2010

Sponsor: Ike Skelton (D-Mo.)

S.1390: National Defense Authorization Act for Fiscal Year 2010

Sponsor: Carl Levin (D-Mich.)

S.1649: WMD Prevention and Preparedness Act of 2009

Sponsor: Joseph I. Lieberman (I-Conn.)

H.R.3663: To amend title XVIII of the Social Security Act to delay the date on...

Sponsor: Zack Space (D-Ohio)

H.R.2891: Access to Frontline Health Care Act of 2009

Sponsor: Bruce Braley (D-Iowa)

H.R.3200: America's Affordable Health Choices Act of 2009

Sponsor: John D. Dingell (D-Mich.)

H.R.3590: Patient Protection and Affordable Care Act

Sponsor: Charles B. Rangel (D-N.Y.)

H.R.4872: Health Care and Education Reconciliation Act of 2010

Sponsor: John M. Spratt Jr. (D-S.C.)

H.R.1166: E-fencing Enforcement Act of 2009

Sponsor: Robert C. Scott (D-Va.)

H.R.1173: Organized Retail Crime Act of 2009

Sponsor: Brad Ellsworth (D-Ind.)

S.470: Combating Organized Retail Crime Act of 2009

Sponsor: Richard J. Durbin (D-Ill.)

S.195: Taxpayer Protection Act

Sponsor: Byron L. Dorgan (D-N.D.)

H.R.3700: Health Care Bill of Rights Act

Sponsor: Phil Gingrey (R-Ga.)

H.R.3202: Water Protection and Reinvestment Act of 2009

Sponsor: Earl Blumenauer (D-Ore.)

H.R.971: Community Pharmacy Fairness Act of 2007

Sponsor: Anthony Weiner (D-N.Y.)

S.2161: Community Pharmacy Fairness Act of 2007

Sponsor: Johnny Isakson (R-Ga.)

H.R.2900: Food and Drug Administration Amendments Act of 2007

Sponsor: John D. Dingell (D-Mich.)

H.R.4: Medicare Prescription Drug Price Negotiation Act of 2007

Sponsor: John D. Dingell (D-Mich.)

S.3: Medicare Prescription Drug Price Negotiation Act of 2007

Sponsor: Harry Reid (D-Nev.)

H.R.1474: Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims...

Sponsor: Marion Berry (D-Ark.)

H.R.5839: Safeguarding America's Pharmaceuticals Act of 2008

Sponsor: Steve Buyer (R-Ind.)

H.R.6852: Community Protection and Response Act of 2008

Sponsor: Carolyn B. Maloney (D-N.Y.)

S.1693: Wired for Health Care Quality Act

Sponsor: Edward M. Kennedy (D-Mass.)

S.980: Ryan Haight Online Pharmacy Consumer Protection Act of 2008

Sponsor: Dianne Feinstein (D-Calif.)

H.R.3140: Saving Our Community Pharmacies Act of 2007

Sponsor: Nancy E. Boyda (D-Kan.)

S.1951: Fair Medicaid Drug Payment Act of 2007

Sponsor: Max Baucus (D-Mont.)

S.1954: Pharmacy Access Improvement (PhAIm) Act of 2007

Sponsor: Max Baucus (D-Mont.)

H.R.3700: Fair Medicaid Drug Payment Act of 2007

Sponsor: Frank Pallone (D-N.J.)

H.R.6357: PRO(TECH)T Act of 2008

Sponsor: John D. Dingell (D-Mich.)

H.R.6331: Medicare Improvements for Patients and Providers Act of 2008

Sponsor: Charles B. Rangel (D-N.Y.)

S.2499: Medicare, Medicaid, and SCHIP Extension Act of 2007

Sponsor: Max Baucus (D-Mont.)

H.R.2006: Secure Visa Waiver Travel Act

Sponsor: Bennie Thompson (D-Miss.)

H.R.1585: National Defense Authorization Act for Fiscal Year 2008

Sponsor: Ike Skelton (D-Mo.)

H.R.4986: National Defense Authorization Act for Fiscal Year 2008

Sponsor: Ike Skelton (D-Mo.)

S.1547: National Defense Authorization Act for Fiscal Year 2008

Sponsor: Carl Levin (D-Mich.)

H.R.4236: MONITOR Act of 2017

Sponsor: Brian Fitzpatrick (R-Pa.)

H.R.3991: Expanded Access to Opioid Abuse Treatment Act of 2017

Sponsor: Michelle Lujan Grisham (D-N.M.)

H.R.4275: Empowering Pharmacists in the Fight Against Opioid Abuse Act

Sponsor: Mark DeSaulnier (D-Calif.)

H.R.1: An Act to provide for reconciliation pursuant to titles II and V of the...

Sponsor: Kevin Brady (R-Texas)

H.R.4408: Opioid Addiction Prevention Act of 2017

Sponsor: John Katko (R-N.Y.)

S.2460: Every Prescription Conveyed Securely Act

Sponsor: Michael Bennet (D-Colo.)

H.R.5219: Opioid Prescription Verification Act of 2018

Sponsor: Rodney Davis (R-Ill.)

S.2456: CARA 2.0 Act of 2018

Sponsor: Rob Portman (R-Ohio)

H.R.5311: CARA 2.0 Act of 2018

Sponsor: Marsha Blackburn (R-Tenn.)

H.R.5202: Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018

Sponsor: Ryan Costello (R-Pa.)

S.2553: Know the Lowest Price Act of 2018

Sponsor: Debbie Stabenow (D-Mich.)

S.2554: Patient Right to Know Drug Prices Act

Sponsor: Susan Collins (R-Maine)

H.R.5343: Prescription Transparency Act of 2018

Sponsor: Buddy Carter (R-Ga.)

H.R.5009: Jessie's Law

Sponsor: Tim Walberg (R-Mich.)

H.R.5676: Stop Excessive Narcotics in our Retirement Communities Protection Act of...

Sponsor: Tom MacArthur (R-N.J.)

H.R.5773: Preventing Addiction for Susceptible Seniors Act of 2018

Sponsor: Peter Roskam (R-Ill.)

H.R.5687: SOUND Disposal and Packaging Act

Sponsor: Richard Hudson (R-N.C.)

H.R.5812: Creating Opportunities that Necessitate New and Enhanced Connections...

Sponsor: Morgan Griffith (R-Va.)

H.R.5801: Medicaid Providers Are Required To Note Experiences in Record Systems to...

Sponsor: Morgan Griffith (R-Va.)

H.R.6: SUPPORT for Patients and Communities Act

Sponsor: Greg Walden (R-Ore.)

H.R.5808: Medicaid Pharmaceutical Home Act of 2018

Sponsor: Gus Bilirakis (R-Fla.)

H.R.5675: To amend title XVIII of the Social Security Act to require prescription...

Sponsor: Gus Bilirakis (R-Fla.)

S.2680: Opioid Crisis Response Act of 2018

Sponsor: Lamar Alexander (R-Tenn.)

S.2645: Access to Increased Drug Disposal Act of 2018

Sponsor: Joni Ernst (R-Iowa)

H.R.5628: Access to Increased Drug Disposal Act of 2018

Sponsor: David McKinley (R-W.Va.)

H.R.6144: Know the Lowest Price Act of 2018

Sponsor: Lloyd Doggett (D-Texas)

H.R.6143: Patient Right to Know Drug Prices Act

Sponsor: Lloyd Doggett (D-Texas)

H.R.5958: Phair Pricing Act of 2018

Sponsor: Doug Collins (R-Ga.)

H.R.6600: DEA Order Clearinghouse Act of 2018

Sponsor: Leonard Lance (R-N.J.)

S.3282: DEA Order Clearinghouse Act of 2018

Sponsor: Cory Gardner (R-Colo.)

H.R.6688: ALERT Act of 2018

Sponsor: Tom MacArthur (R-N.J.)

H.R.6157: Department of Defense and Labor, Health and Human Services, and...

Sponsor: Kay Granger (R-Texas)

H.R.6733: Know the Cost Act of 2018

Sponsor: Buddy Carter (R-Ga.)

H.R.6641: COST Act

Sponsor: Erik Paulsen (R-Minn.)

H.R.7339: Medicare for America Act of 2018

Sponsor: Rosa DeLauro (D-Conn.)

H.R.127: CARERS Act of 2019

Sponsor: Steve Cohen (D-Tenn.)

H.R.171: LUMMA

Sponsor: Morgan Griffith (R-Va.)

H.R.1845: ALERT Act of 2019

Sponsor: Ann McLane Kuster (D-N.H.)

S.516: Prescription Drug Monitoring Act of 2019

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1588: Ending Federal Marijuana Prohibition Act of 2019

Sponsor: Tulsi Gabbard (D-Hawaii)

H.R.1607: Fairness to Pet Owners Act of 2019

Sponsor: Matt Cartwright (D-Pa.)

S.474: Stopping the Pharmaceutical Industry from Keeping drugs Expensive...

Sponsor: Ron Wyden (D-Ore.)

H.R.447: Affordable and Safe Prescription Drug Importation Act

Sponsor: Elijah E. Cummings (D-Md.)

S.97: Affordable and Safe Prescription Drug Importation Act

Sponsor: Bernard Sanders (ID-Vt.)

S.61: Safe and Affordable Drugs from Canada Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.478: Safe and Affordable Drugs from Canada Act of 2019

Sponsor: Chellie Pingree (D-Maine)

S.102: Prescription Drug Price Relief Act of 2019

Sponsor: Bernard Sanders (ID-Vt.)

H.R.465: Prescription Drug Price Relief Act of 2019

Sponsor: Ro Khanna (D-Calif.)

H.R.1478: Affordable Insulin Act of 2019

Sponsor: Peter Welch (D-Vt.)

S.3: Keeping Health Insurance Affordable Act of 2019

Sponsor: Benjamin L. Cardin (D-Md.)

H.R.965: CREATES Act of 2019

Sponsor: David Cicilline (D-R.I.)

S.340: CREATES Act of 2019

Sponsor: Patrick J. Leahy (D-Vt.)

H.R.1332: Fair Care Act of 2019

Sponsor: Bruce Westerman (R-Ark.)

S.637: CURE High Drug Prices Act

Sponsor: Richard Blumenthal (D-Conn.)

H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019

Sponsor: Bobby L. Rush (D-Ill.)

S.657: A bill to amend title XXVII of the Public Health Service Act to...

Sponsor: Mike Braun (R-Ind.)

S.709: Prescription Drug Pricing Dashboard Act

Sponsor: Bob Casey (D-Pa.)

H.R.803: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Peter Welch (D-Vt.)

S.988: Improving Transparency and Accuracy in Medicare Part D Spending Act

Sponsor: Shelley Moore Capito (R-W.Va.)

H.R.1034: Phair Pricing Act of 2019

Sponsor: Doug Collins (R-Ga.)

S.640: Phair Pricing Act of 2019

Sponsor: John Kennedy (R-La.)

H.R.1035: Prescription Drug Price Transparency Act

Sponsor: Doug Collins (R-Ga.)

S.475: RxCAP Act of 2019

Sponsor: Ron Wyden (D-Ore.)

S.476: Creating Transparency to Have Drug Rebates Unlocked (C–THRU) Act of 2019

Sponsor: Ron Wyden (D-Ore.)

H.R.107: To amend title XIX of the Social Security Act to sunset the limit on the...

Sponsor: Michael C. Burgess (R-Texas)

H.R.448: Medicare Drug Price Negotiation Act

Sponsor: Elijah E. Cummings (D-Md.)

S.99: Medicare Drug Price Negotiation Act

Sponsor: Bernard Sanders (ID-Vt.)

H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019

Sponsor: Peter Welch (D-Vt.)

H.R.1346: Medicare Buy-In and Health Care Stabilization Act of 2019

Sponsor: Brian Higgins (D-N.Y.)

H.R.366: Insulin Access for All Act of 2019

Sponsor: Bobby L. Rush (D-Ill.)

S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019

Sponsor: Amy Klobuchar (D-Minn.)

S.205: Right Rebate Act of 2019

Sponsor: Ron Wyden (D-Ore.)

H.R.937: Right Rebate Act of 2019

Sponsor: Kurt Schrader (D-Ore.)

H.R.1046: Medicare Negotiation and Competitive Licensing Act of 2019

Sponsor: Lloyd Doggett (D-Texas)

S.377: Medicare Negotiation and Competitive Licensing Act of 2019

Sponsor: Sherrod Brown (D-Ohio)

H.R.1781: Payment Commission Data Act of 2019

Sponsor: Buddy Carter (R-Ga.)

S.801: A bill to amend titles XVIII and XIX of the Social Security Act to...

Sponsor: Catherine Cortez Masto (D-Nev.)

H.R.2113: Prescription Drug STAR Act

Sponsor: Richard E. Neal (D-Mass.)

H.R.2115: Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act

Sponsor: Abigail Spanberger (D-Va.)

H.R.1323: Rural Hospital Frontier Fairness Act

Sponsor: Collin C. Peterson (D-Minn.)

S.551: REFUND Act of 2019

Sponsor: Richard J. Durbin (D-Ill.)

S.691: Medicare Extra Rx HELP Act of 2019

Sponsor: Bob Casey (D-Pa.)

S.773: Telehealth Innovation and Improvement Act of 2019

Sponsor: Cory Gardner (R-Colo.)

S.814: Expanding Access to Diabetes Self-Management Training Act of 2019

Sponsor: Jeanne Shaheen (D-N.H.)

H.R.1384: Medicare for All Act of 2019

Sponsor: Pramila Jayapal (D-Wash.)

S.1129: Medicare for All Act of 2019

Sponsor: Bernard Sanders (ID-Vt.)

H.R.1959: Preserving Patient Access to Compounded Medications Act of 2019

Sponsor: Morgan Griffith (R-Va.)

S.172: Health Insurance Tax Relief Act of 2019

Sponsor: Cory Gardner (R-Colo.)

H.R.1398: Health Insurance Tax Relief Act of 2019

Sponsor: Ami Bera (D-Calif.)

S.215: Death Tax Repeal Act of 2019

Sponsor: John Thune (R-S.D.)

H.R.218: Death Tax Repeal Act

Sponsor: Jason Smith (R-Mo.)

S.1089: Restoring Access to Medication Act of 2019

Sponsor: Pat Roberts (R-Kan.)

H.R.1922: Restoring Access to Medication Act of 2019

Sponsor: Ron Kind (D-Wis.)

S.977: Transparent Drug Pricing Act of 2019

Sponsor: Rick Scott (R-Fla.)

S.1895: Lower Health Care Costs Act

Sponsor: Lamar Alexander (R-Tenn.)

H.R.2296: More Efficient Tools to Realize Information for Consumers Act

Sponsor: Jan Schakowsky (D-Ill.)

H.R.3417: Beneficiary Education Tools, Telehealth, and Extenders Reauthorization...

Sponsor: Richard E. Neal (D-Mass.)

H.R.3408: Shop Rx Act of 2019

Sponsor: Jodey Arrington (R-Texas)

S.1384: Prescription Drug Rebate Reform Act of 2019

Sponsor: Mitt Romney (R-Utah)

H.R.2376: Prescription Pricing for the People Act of 2019

Sponsor: Doug Collins (R-Ga.)

S.1227: Prescription Pricing for the People Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3223: Pharmacy Benefit Manager Accountability Study Act of 2019

Sponsor: Roger Marshall (R-Kan.)

S.1532: Pharmacy Benefit Manager Accountability Study Act of 2019

Sponsor: Marsha Blackburn (R-Tenn.)

S.1149: Main Street Tax Certainty Act

Sponsor: Steve Daines (R-Mont.)

H.R.216: Main Street Tax Certainty Act

Sponsor: Jason Smith (R-Mo.)

H.R.3947: Competition Prescription Act of 2019

Sponsor: Mark Meadows (R-N.C.)

H.R.2279: Safe Step Act

Sponsor: Raul Ruiz (D-Calif.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

S.2543: Prescription Drug Pricing Reduction Act of 2019

Sponsor: Charles E. Grassley (R-Iowa)

S.2447: American Energy Opportunity Act of 2019

Sponsor: Martin Heinrich (D-N.M.)

H.R.4810: Opioid Prescription Verification Act of 2019

Sponsor: Rodney Davis (R-Ill.)

S.3070: Preventing Pill Mills Through Data Sharing Act

Sponsor: Dianne Feinstein (D-Calif.)

H.R.19: Lower Costs, More Cures Act of 2019

Sponsor: Greg Walden (R-Ore.)

S.3129: Lower Costs, More Cures Act of 2019

Sponsor: Michael D. Crapo (R-Idaho)

S.2771: MPACT Act

Sponsor: Richard Blumenthal (D-Conn.)

S.1861: Streamlining Part D Appeals Process Act

Sponsor: Benjamin L. Cardin (D-Md.)

H.R.3924: Streamlining Part D Appeals Process Act

Sponsor: Thomas Suozzi (D-N.Y.)

H.R.4946: Ensuring Seniors Access to Local Pharmacies Act of 2019

Sponsor: Peter Welch (D-Vt.)

H.R.5281: Drug Price Transparency in Medicaid Act of 2019

Sponsor: Buddy Carter (R-Ga.)

H.R.5442: Lowest Price for Patients Act

Sponsor: Katie Porter (D-Calif.)

H.R.1865: Further Consolidated Appropriations Act, 2020

Sponsor: Bill Pascrell Jr. (D-N.J.)

H.R.5198: Patients' Right to Know Their Medication Act of 2019

Sponsor: Jared Golden (D-Maine)

H.R.5304: PBM Transparency in Prescription Drug Costs Act

Sponsor: Kurt Schrader (D-Ore.)

S.3548: CARES Act

Sponsor: Mitch McConnell (R-Ky.)

H.R.6201: Families First Coronavirus Response Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.6776: JOBS Credit Act of 2020

Sponsor: Stephanie Murphy (D-Fla.)

H.R.6821: Small Business Expense Protection Act of 2020

Sponsor: George Holding (R-N.C.)

S.3612: Small Business Expense Protection Act of 2020

Sponsor: John Cornyn (R-Texas)

H.R.7079: Clean Start: Back to Work Tax Credit Act

Sponsor: Darin M. LaHood (R-Ill.)

S.3932: TRICARE Retail Pharmacy Prescription Medication Expansion Act of 2020

Sponsor: Mike Rounds (R-S.D.)

S.4049: National Defense Authorization Act for Fiscal Year 2021

Sponsor: James M. Inhofe (R-Okla.)

H.R.6395: William M. (Mac) Thornberry National Defense Authorization Act for...

Sponsor: Adam Smith (D-Wash.)

H.R.748: CARES Act

Sponsor: Joe Courtney (D-Conn.)

H.R.6800: The Heroes Act

Sponsor: Nita M. Lowey (D-N.Y.)

H.R.266: Paycheck Protection Program and Health Care Enhancement Act

Sponsor: Betty McCollum (D-Minn.)

H.R.7010: Paycheck Protection Program Flexibility Act of 2020

Sponsor: Dean Phillips (D-Minn.)

H.R.3878: Block, Report, And Suspend Suspicious Shipments Act of 2020

Sponsor: David McKinley (R-W.Va.)

H.R.4812: Ensuring Compliance Against Drug Diversion Act of 2020

Sponsor: Morgan Griffith (R-Va.)

H.R.4814: Suspicious Order Identification Act of 2019

Sponsor: Doris Matsui (D-Calif.)

S.4199: Prescription Drug Pricing Reduction Act of 2020

Sponsor: Charles E. Grassley (R-Iowa)

H.R.7528: Get America Back to Work Act

Sponsor: Garret Graves (R-La.)

S.4317: SAFE TO WORK Act

Sponsor: John Cornyn (R-Texas)

H.R.2513: Corporate Transparency Act of 2019

Sponsor: Carolyn B. Maloney (D-N.Y.)

S.4117: Paycheck Protection Small Business Forgiveness Act

Sponsor: Kevin Cramer (R-N.D.)

H.R.7777: Paycheck Protection Small Business Forgiveness Act

Sponsor: Chrissy Houlahan (D-Pa.)

H.R.8265: To amend the Small Business Act and the CARES Act to establish a program...

Sponsor: Steven J. Chabot (R-Ohio)

S.4321: Continuing Small Business Recovery and Paycheck Protection Program Act

Sponsor: Marco Rubio (R-Fla.)

S.4773: Continuing the Paycheck Protection Program Act

Sponsor: Susan Collins (R-Maine)

S.4775: Delivering Immediate Relief to America's Families, Schools and Small...

Sponsor: Mitch McConnell (R-Ky.)

H.R.133: Consolidated Appropriations Act, 2021

Sponsor: Henry Cuellar (D-Texas)

H.R.280: PDMPs Help Patients Act of 2021

Sponsor: David McKinley (R-W.Va.)

S.298: Pharmacy Benefit Manager Accountability Study Act of 2021

Sponsor: Marsha Blackburn (R-Tenn.)

H.R.1829: Pharmacy Benefit Manager Accountability Study Act of 2021

Sponsor: Diana Harshbarger (R-Tenn.)

S.617: Death Tax Repeal Act of 2021

Sponsor: John Thune (R-S.D.)

H.R.1712: Death Tax Repeal Act

Sponsor: Jason Smith (R-Mo.)

S.225: Competition and Antitrust Law Enforcement Reform Act of 2021

Sponsor: Amy Klobuchar (D-Minn.)

H.R.1799: PPP Extension Act of 2021

Sponsor: Carolyn Bourdeaux (D-Ga.)

H.R.1319: American Rescue Plan Act of 2021

Sponsor: John Yarmuth (D-Ky.)

H.R.2355: Opioid Prescription Verification Act of 2021

Sponsor: Rodney Davis (R-Ill.)

H.R.3554: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Peter Welch (D-Vt.)

S.1909: Pharmacy DIR Reform To Reduce Senior Drug Costs Act

Sponsor: Jon Tester (D-Mont.)

H.R.2608: Ensuring Seniors Access to Local Pharmacies Act of 2021

Sponsor: Peter Welch (D-Vt.)

H.R.2759: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: G. K. Butterfield (D-N.C.)

S.1362: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.3682: Improving Transparency to Lower Drug Costs Act of 2021

Sponsor: Abigail Spanberger (D-Va.)

H.R.2484: Lowest Price for Patients Act

Sponsor: Katie Porter (D-Calif.)

H.R.3: Elijah E. Cummings Lower Drug Costs Now Act

Sponsor: Frank Pallone (D-N.J.)

H.R.19: Lower Costs, More Cures Act of 2021

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.2164: Lower Costs, More Cures Act of 2021

Sponsor: Michael D. Crapo (R-Idaho)

H.R.3173: Improving Seniors’ Timely Access to Care Act of 2021

Sponsor: Suzan K. DelBene (D-Wash.)

H.R.3655: Vaccine Injury Compensation Modernization Act of 2021

Sponsor: Lloyd Doggett (D-Texas)

H.R.3656: Vaccine Access Improvement Act of 2021

Sponsor: Lloyd Doggett (D-Texas)

H.R.3662: Patient Access to Urgent-Use Pharmacy Compounding Act of 2021

Sponsor: Morgan Griffith (R-Va.)

H.R.1381: Main Street Tax Certainty Act

Sponsor: Jason Smith (R-Mo.)

S.480: Main Street Tax Certainty Act

Sponsor: Steve Daines (R-Mont.)

S.1388: Prescription Pricing for the People Act of 2021

Sponsor: Charles E. Grassley (R-Iowa)

H.R.603: Raise the Wage Act of 2021

Sponsor: Robert C. Scott (D-Va.)

S.53: Raise the Wage Act of 2021

Sponsor: Bernard Sanders (ID-Vt.)

H.R.768: Block, Report, And Suspend Suspicious Shipments Act of 2021

Sponsor: David McKinley (R-W.Va.)

H.R.4121: PRO Seniors Act

Sponsor: Jodey Arrington (R-Texas)

H.R.3684: Infrastructure Investment and Jobs Act

Sponsor: Peter A. DeFazio (D-Ore.)

H.R.4390: PROTECT 340B Act of 2021

Sponsor: David McKinley (R-W.Va.)

S.1574: Long-Term Care Pharmacy Definition Act of 2021

Sponsor: Tim Scott (R-S.C.)

H.R.7: Paycheck Fairness Act

Sponsor: Rosa DeLauro (D-Conn.)

H.R.2583: PPP Equity Act of 2021

Sponsor: Ashley Hinson (R-Iowa)

H.R.5237: Reduced Costs and Continued Cures Act of 2021

Sponsor: Scott Peters (D-Calif.)

H.R.5376: Inflation Reduction Act of 2022

Sponsor: John Yarmuth (D-Ky.)

H.R.5804: Expanding Access to Diabetes Self-Management Training Act of 2021

Sponsor: Kim Schrier (D-Wash.)

H.R.6101: Drug Price Transparency in Medicaid Act of 2021

Sponsor: Buddy Carter (R-Ga.)

H.R.5632: Long-Term Care Pharmacy Definition Act of 2021

Sponsor: Kurt Schrader (D-Ore.)

H.R.6005: Access to Birth Control Act

Sponsor: Carolyn B. Maloney (D-N.Y.)

S.3700: Affordable Insulin Now Act

Sponsor: Raphael Warnock (D-Ga.)

H.R.7213: Equitable Community Access to Pharmacist Services Act

Sponsor: Ron Kind (D-Wis.)

H.R.6000: Cures 2.0 Act

Sponsor: Diana DeGette (D-Colo.)

H.R.6519: Patients’ Right to Know Their Medication Act of 2022

Sponsor: Jared Golden (D-Maine)

H.R.7666: Restoring Hope for Mental Health and Well-Being Act of 2022

Sponsor: Frank Pallone (D-N.J.)

H.R.7559: Prescription Information Modernization Act of 2022

Sponsor: Mikie Sherrill (D-N.J.)

S.4293: Pharmacy Benefit Manager Transparency Act of 2022

Sponsor: Maria Cantwell (D-Wash.)

H.R.8988: EPCS 2.0 Act

Sponsor: Tom O'Halleran (D-Ariz.)

S.4858: Cooper Davis Act

Sponsor: Roger Marshall (R-Kan.)

H.R.9092: Family and Small Business Taxpayer Protection Act

Sponsor: Adrian Smith (R-Neb.)

S.288: TRANSPLANT Act of 2021

Sponsor: Jack Reed (D-R.I.)

H.R.3843: Merger Filing Fee Modernization Act of 2022

Sponsor: Joe Neguse (D-Colo.)

H.R.501: Block, Report, and Suspend Suspicious Shipments Act

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.1613: Drug Price Transparency in Medicaid Act of 2023

Sponsor: Buddy Carter (R-Ga.)

S.1038: Drug Price Transparency in Medicaid Act of 2023

Sponsor: Peter Welch (D-Vt.)

H.R.167: Patient Access to Urgent-Use Pharmacy Compounding Act of 2023

Sponsor: Morgan Griffith (R-Va.)

H.R.382: Pandemic is Over Act

Sponsor: Brett Guthrie (R-Ky.)

S.1108: Death Tax Repeal Act of 2023

Sponsor: John Thune (R-S.D.)

S.127: Pharmacy Benefit Manager Transparency Act of 2023

Sponsor: Maria Cantwell (D-Wash.)

S.113: Prescription Pricing for the People Act of 2023

Sponsor: Charles E. Grassley (R-Iowa)

S.2052: Protect Patient Access to Pharmacies Act

Sponsor: Jon Tester (D-Mont.)

H.R.2880: Protecting Patients Against PBM Abuses Act

Sponsor: Buddy Carter (R-Ga.)

H.R.1770: Equitable Community Access to Pharmacist Services Act

Sponsor: Adrian Smith (R-Neb.)

S.1491: Pharmacy and Medically Underserved Areas Enhancement Act

Sponsor: Charles E. Grassley (R-Iowa)

H.R.2816: Pharmacy Benefit Manager Sunshine and Accountability Act

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.3281: Transparent PRICE Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.3282: Promoting Transparency and Healthy Competition in Medicare Act

Sponsor: Diana Harshbarger (R-Tenn.)

H.R.3561: PATIENT Act of 2023

Sponsor: Cathy McMorris Rodgers (R-Wash.)

S.1967: PBM Act

Sponsor: Robert Menendez (D-N.J.)

S.2129: Ensuring Access to Lower-Cost Medicines for Seniors Act

Sponsor: James Lankford (R-Okla.)

H.R.2679: Pharmacy Benefits Manager Accountability Act

Sponsor: Ann McLane Kuster (D-N.H.)

H.R.3008: Drug Shortage Prevention Act of 2023

Sponsor: Sara Jacobs (D-Calif.)

S.1339: Pharmacy Benefit Manager Reform Act

Sponsor: Bernard Sanders (ID-Vt.)

S.1542: DRUG Act

Sponsor: Roger Marshall (R-Kan.)

H.R.2670: National Defense Authorization Act for Fiscal Year 2024

Sponsor: Mike D. Rogers (R-Ala.)

S.2666: EPCS 2.0 Act

Sponsor: Margaret Hassan (D-N.H.)

S.2477: Equitable Community Access to Pharmacist Services Act

Sponsor: John Thune (R-S.D.)

S.2405: Strengthening Pharmacy Access for Seniors Act

Sponsor: John Thune (R-S.D.)

S.2973: Modernizing and Ensuring PBM Accountability Act

Sponsor: Ron Wyden (D-Ore.)

H.R.5378: Lower Costs, More Transparency Act

Sponsor: Cathy McMorris Rodgers (R-Wash.)

H.R.5385: Medicare PBM Accountability Act

Sponsor: Greg Landsman (D-Ohio)

H.R.5393: To amend title XVIII of the Social Security Act to ensure fair...

Sponsor: Morgan Griffith (R-Va.)

H.R.5400: NO PBMs Act

Sponsor: Buddy Carter (R-Ga.)

S.2436: NO PBMs Act

Sponsor: Joe Manchin III (D-W.Va.)

H.R.5142: Vaccine Injury Compensation Modernization Act of 2023

Sponsor: Lloyd Doggett (D-Texas)

H.R.5143: Vaccine Access Improvement Act of 2023

Sponsor: Lloyd Doggett (D-Texas)

S.2305: Biosimilar Red Tape Elimination Act

Sponsor: Mike Lee (R-Utah)

H.R.1173: Patients’ Right to Know Their Medication Act of 2023

Sponsor: Buddy Carter (R-Ga.)

H.R.4794: Dietary Supplements Access Act

Sponsor: Darin M. LaHood (R-Ill.)

H.R.4035: Protecting Small Business Information Act of 2023

Sponsor: Patrick T. McHenry (R-N.C.)

S.2623: Protecting Small Business Information Act of 2023

Sponsor: Mike Rounds (R-S.D.)

S.3430: Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

Sponsor: Ron Wyden (D-Ore.)

H.R.6283: DRUG Act

Sponsor: Mariannette Miller-Meeks (R-Iowa)

H.R.4366: Consolidated Appropriations Act, 2024

Sponsor: John Carter (R-Texas)

H.R.2882: Further Consolidated Appropriations Act, 2024

Sponsor: Juan Ciscomani (R-Ariz.)

Show All Mentioned Bills

Lobbyists

Lobbyists named here were listed on a filing related to this lobbying engagement. They may not be working on it now. Occasionally, a single lobbyist whose name is spelled two different ways on filings may be represented twice here.

Lobbyist	Covered positions?
Michael Tomberlin	Chief of Staff, Leg Director, US House of Reps.
Kevin Schweers	Deputy Assistant Secretary, Public Affairs, Health and Human Services
John Coster	Professional Staff Member, Senate Aging Comm. Health Analyst, Cong. Off. of Technology Assess.
Shawn Friesen	Legislative Director, House of Representives Legislative Director, House of Representatives
Stephen Cote	OMB Associate Director for Legislative Affairs OMB Dep. Assoc. Director for Legislative Affairs Congressman Lincoln Diaz-Balart - Administrative Assistant Congressman Diaz-Balart - Legislative Director Congressman Diaz-Balart - Legislative Asst. House Select Committee on Homeland Security House Committee on Rules - Rules Associate US Senator Connie Mack - Legislative Asst. US Senator Mack - Legislative Correspondent US Senate Mack - Staff Assistant
Stephne Cote	- Policy Coordinator
Phillip Harbison	Legislative Director, Rep H. Morgan Griffith
Peter Mihalick	Legislative Director, Rep. Barbara Comstock; Legislative Director, Rep. Rod Blum; Legislative Counsel, Rep. Tom Marino
Kaitlin Krell	Legislative Aide, Sen. Cynthia Lummis
CHARLIE SEWELL	n/a
CHRISTOPHER NAVE	n/a
TONY LEE	n/a
ANNE CASSITY	n/a
EDWARD GERETY	n/a
JOHN M. RECTOR	n/a
Karry LaViolette	n/a
Susan Pilch	n/a
Ronna Hauser	n/a
Mike Tomberlin	n/a
Karry La Violette	n/a
Steve Pfister	n/a
Mary O'Dea Ahearn	n/a
Matthew DiLoreto	n/a
Steven Pfister	n/a
Mary O'Day Ahearn	n/a
David Sanders	n/a
Cynthia Blankenship	n/a
Adnan Jalil	n/a
Susan Janeczko	n/a
Gary Haulmark	n/a
Chris Parinello	n/a
Brian Anderson	n/a
Thomas Riddleberger	n/a
Jim Hippe	n/a
Charles Sewell	n/a
Elizabeth Bartlett	n/a
Kala Shankle	n/a
Reema Taneja	n/a
Shion Chang	n/a
Matthew Seiler	n/a
Steve Postal	n/a

Disclosures Filed

Once a lobbying engagement begins, the lobbyist or firm is required to file updates four times a year. Those updates sometimes change which lobbyists are involved or add new issues being discussed. When lobbyists stop working for a client, the firm is also supposed to file a report disclosing the end of the relationship.

0th Quarter, 2005

Registration

0th Quarter, 2005

Registration

1st Quarter, 2024

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 22. Original Filing: 301574123.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1613 / S. 1038, the Drug Price Transparency in Medicaid Act; S. 2052, the Protect Patient Access to Pharmacies Act; H.R. 2880, the Protecting Patients Against PBM Abuses Act; H.R. 1770 / S. 2477, the Equitable Community Access to Pharmacist Services Act; S. 1491, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 2816, the PBM Sunshine and Accountability Act; H.R. 3281, the Transparent PRICE Act; H.R. 3282, the Promoting Transparency and Healthy Competition in Medicare Act; H.R. 3561, the PATIENT Act; S. 1967, the Patients Before Middlemen (PBM) Act; S. 2129, the Ensuring Access to Lower-Cost Medicines for Seniors Act; S. 2405, the Strengthening Pharmacy Access for Seniors Act; S. 2973, the Modernizing and Ensuring PBM Accountability Act; H.R. 5378, the Lower Costs, More Transparency Act; H.R.5385, the Medicare PBM Accountability Act; H.R. 5393, to amend title XVIII of the Social Security Act to ensure fair assessment of pharmacy performance and quality under Medicare part D, and for other purposes; H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Medicare Transaction Facilitator (MTF) for the Medicare Drug Price Negotiation Program in the Inflation Reduction Act" (IRA; P.L. 117-169); Comments for "Medicare Prescription Payment Plan: Draft Part Two Guidance on Select Topics, Implementation of Section 1860D-2 of the Social Security Act for 2025" (IRA, P.L. 117-169); Comments for Final Rule Document 2022-09375, "Medicare Program, Contract Year 2023 Policy and Technical Changes to the Medicare Advantage and Medicare Prescription Drug Benefit Programs..." (87 FR 27704); Comments for "Advance Notice of Methodological Changes for Calendar Year (CY) 2025 for Medicare Advantage (MA) Capitation Rates and Part C and Part D Payment Policies" (CMS-2024-0006); Request for Information for Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024 H.R.2882, the Further Consolidated Appropriations Act, 2024

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023; Request for Information for "Implementing Interoperable Systems and Processes for Enhanced Drug Distribution Security Requirements Under Section 582(g)(1) of the Federal Food, Drug, and Cosmetic Act" (Docket No. FDA-2023-N-4806); Request for Information on Bipartisan 340B Senate Working Group SUSTAIN 340B Act Discussion Draft; H.R.4366, the Consolidated Appropriations Act, 2024; H.R.2882, the Further Consolidated Appropriations Act, 2024;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2023

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 21. Original Filing: 301534043.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 167, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2023; H.R. 382, the Pandemic is Over Act; H.R. 2679, the Pharmacy Benefits Manager Accountability Act; H.R. 3008, the Drug Shortage Prevention Act; S. 1339, the Pharmacy Benefits Manager Reform Act; S. 1542 / H.R. 6283, the Delinking Revenue from Unfair Gouging Act; H.R. 5142, the Vaccine Injury Compensation Modernization Act of 2023; H.R. 5143, the Vaccine Access Improvement Act of 2023; S. 2305, the Biosimilar Red Tape Elimination Act; H.R. 1173, the Patients Right to Know Their Medication Act of 2023; Proposed rule for Medication Guides: Patient Medication Information (Docket No. FDA-2019-N-5959); Implementation of Public Law 113-54, the Drug Quality and Security Act; Draft Guidance for Industry, Interim Policy on Compounding Using Bulk Drug Substances Under Section 503A of the Federal Food, Drug, and Cosmetic Act, (Docket No. FDA-2015-D-3517); H.R. 5400 / S. 2436, the NO PBMs Act; S.3430,the Better Mental Health Care, Lower-Cost Drugs, and Extenders Act of 2023

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2023

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 11, 2023. Original Filing: 301499245.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2023

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 12, 2023. Original Filing: 301474903.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2023

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 17, 2023. Original Filing: 301453545.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2022

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 13, 2023. Original Filing: 301427371.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3554 / S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act; H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act; H.R. 2759 / S. 1362, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3682, the Improving Transparency to Lower Drug Costs Act; H.R. 2484, the Lowest Price for Patients Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 / S. 2164, the Lower Costs, More Cures Act of 2021; H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021; H.R. 4121, the PRO Seniors Act; Proposed inclusion of Medicaid managed care spread pricing prohibition to pay for H.R. 3684, the Infrastructure Investment and Jobs Act; H.R. 5237, the Reduced Costs and Continued Cures Act of 2021 H.R. 5376, the Build Back Better Act; H.R. 5804, the Expanding Access to Diabetes Self-Management Training Act of 2021; H.R. 6101, the Drug Price Transparency in Medicaid Act of 2021; Part B billing and COVID oral antivirals; S. 3700, the Affordable Insulin Now Act; H.R. 7213, Equitable Community Access to Pharmacist Services Act; CY 2023 Medicare Advantage and Part D Final Rule (CMS-4192-F); Draft legislation, the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act; H.R. 5376, the Inflation Reduction Act of 2022; Draft legislation on pharmacy DIR fee reform

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; H.R. 7559, Prescription Information Modernization Act; Draft legislation, To ensure that private health insurers are able to provide appropriate oversight of entities providing pharmacy benefit manager services; Draft legislation, the PBM Transparency, Accountability, and Reform Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2022

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 13, 2022. Original Filing: 301403637.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2022

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 15, 2022. Original Filing: 301380786.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 3554 / S. 1909, the Pharmacy DIR Reform To Reduce Senior Drug Costs Act; H.R. 2608, the Ensuring Seniors Access to Local Pharmacies Act; H.R. 2759 / S. 1362, the Pharmacy and Medically Underserved Areas Enhancement Act; H.R. 3682, the Improving Transparency to Lower Drug Costs Act; H.R. 2484, the Lowest Price for Patients Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; H.R. 19 / S. 2164, the Lower Costs, More Cures Act of 2021; H.R. 3173, the Improving Seniors Timely Access to Care Act of 2021; H.R. 4121, the PRO Seniors Act; Proposed inclusion of Medicaid managed care spread pricing prohibition to pay for H.R. 3684, the Infrastructure Investment and Jobs Act; H.R. 5237, the Reduced Costs and Continued Cures Act of 2021 H.R. 5376, the Build Back Better Act; H.R. 5804, the Expanding Access to Diabetes Self-Management Training Act of 2021; H.R. 6101, the Drug Price Transparency in Medicaid Act of 2021; Part B billing and COVID oral antivirals; S. 3700, the Affordable Insulin Now Act; H.R. 7213, Equitable Community Access to Pharmacist Services Act; CY 2023 Medicare Advantage and Part D Proposed Rule (CMS-4192-P); Draft legislation, the Improving Needed Safeguards for Users of Lifesaving Insulin Now (INSULIN) Act

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2022

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 15, 2022. Original Filing: 301356828.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 298 / H.R. 1829, the Pharmacy Benefit Manager Accountability Study Act of 2021; H.R. 3655, the Vaccine Injury Compensation Modernization Act of 2021; H.R. 3656, the Vaccine Access Improvement Act of 2021; H.R. 3662, the Patient Access to Urgent-Use Pharmacy Compounding Act of 2021; COVID vaccine distribution; Pharmacist scope of practice, including authorities established by the Public Readiness and Emergency Preparedness (PREP) Act; H.R. 4390, the PROTECT 340B Act of 2021; S. 1574 / H.R. 5632, the Long-Term Care Pharmacy Definition Act of 2021; Provider Relief Fund; Implementation of Pubic Law 113-54, the Drug Quality and Security Act; H.R. 6005, the Access to Birth Control Act; H.R. 6000, Cures 2.0 Act; H.R. 6519, Patients Right to Know Their Medication Act of 2022; Draft legislation, Pharmacy Price Transparency Protection Act; Draft legislation, Prescription Information Modernization Act;

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION amended a lobbying report for in-house lobbying in Q42021 on April 25, 2022 Original Filing: 301373374.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2021

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 18, 2022. Original Filing: 301325467.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2021

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 15, 2021. Original Filing: 301299855.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2021

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 15, 2021. Original Filing: 301276778.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2021

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 19, 2021. Original Filing: 301258749.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2020

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 21, 2021. Original Filing: 301243067.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 474, Stop the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act; H.R. 447 / S. 97, Affordable and Safe Prescription Drug Importation Act; S. 61 / H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 102 / H.R. 465, Prescription Drug Price Relief Act of 2019; H.R.1478, Affordable Insulin Act of 2019; S. 3, Keeping Health Insurance Affordable Act of 2019; H.R 965 / S. 340, CREATES Act of 2019; H.R. 1332, Fair Care Act of 2019; S. 637, CURE High Drug Prices Act; H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019; S. 657, A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits; S. 709, Prescription Drug Pricing Dashboard Act; S. 977, Transparent Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act; H.R. 2296, FAIR Drug Pricing Act of 2019; H.R. 3947, the Competition Prescription Act of 2019; H.R. 2279, the Safe Step Act; H.R. 3, the Elijah E. Cummings Lower Drug Costs Now Act; S. 2543, the Prescription Drug Pricing Reduction Act of 2019; H.R. 19 / S. 3129, the Lower Costs, More Cures Act of 2019; S. 4199, the Prescription Drug Pricing Reduction Act of 2020

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 803 / S. 988, Improving Transparency and Accuracy in Medicare Part D Drug Spending Act; H.R. 1034 / S. 640, Phair Pricing Act of 2019; H.R. 1035, Prescription Drug Price Transparency Act, S. 475, Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act, S. 476, Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act; H.R. 107, To amend title XIX of the Social Security Act to sunset the limit on the maximum rebate amount for single source drugs and innovator multiple source drugs; H.R.448 / S. 99, Medicare Drug Price Negotiation Act; H.R. 275, Medicare Prescription Drug Price Negotiation Act of 2019; H.R. 1346, Medicare Buy-In and Health Care Stabilization Act of 2019; H.R. 366, Insulin Access for All Act of 2019; S. 62, Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019; S. 205 / H.R. 937, Right Rebate Act of 2019; H.R. 1046 / S. 377, Medicare Negotiation and Competitive Licensing Act of 2019; H.R. 1781 / S. 801, the Payment Commission Data Act of 2019; H.R. 2113, Prescription Drug Sunshine, Transparency, Accountability and Reporting (STAR) Act of 2019; H.R. 2115, To amend title XI of the Social Security Act to provide greater transparency of discounts provided by drug manufacturers; Proposed rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"; Proposed rule, "Fraud and Abuse; Removal of Safe Harbor Protection for Rebates Involving Prescription Pharmaceuticals and Creation of New Safe Harbor Protection for Certain Point-of-Sale Reductions in Price on Prescription Pharmaceuticals and Certain Pharmacy Benefit Manager Service Fees, OIG-0936-P"; Proposed rule, Medicaid Program; Medicaid and Childrens Health Insurance Plan (CHIP) Managed Care - CMS-2408-P; H.R. 1323, Rural Hospital Frontier Fairness Act; S. 551, REFUND Act of 2019; S. 691, Medicare Extra Rx HELP Act of 2019; S. 773, Telehealth Innovation and Improvement Act of 2019; S. 814, Expanding Access to Diabetes Self-Management Training Act of 2019; H.R. 1384 / S. 1129, Medicare for All Act of 2019; H.R. 3417, The Beneficiary Education Tools, Telehealth, and Extenders Reauthorization Act of 2019; H.R. 3408, Shop Rx Act of 2019; S. 1384, Prescription Drug Rebate Reform Act of 2019; H.R. 2113, Prescription Drug STAR Act; H.R. 2115, Public Disclosure of Drug Discounts Act S. 2447, the Phair Relief Act; S. 2771, the Protecting Home Oxygen and Medical Equipment Act of 2019; S. 1861 / H.R. 3924, the Streamlining Part D Appeals Process Act; H.R. 4946, the Ensuring Seniors Access to Local Pharmacies Act of 2019; H.R. 5281, the Drug Price Transparency in Medicaid Act of 2019; H.R. 5442, the Lowest Price for Patients Act; Report language for H.R.1865, the Further Consolidated Appropriations Act; Pharmacist Provider Status draft legislation

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 748 / S. 3548, the Coronavirus Aid, Relief, and Economic Security (CARES) Act; H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions (HEROES) Act; H.R. 266, the Paycheck Protection Program and Health Care Enhancement Act; H.R. 7010, the Paycheck Protection Program Flexibility Act of 2020; H.R. 2513, the Corporate Transparency Act of 2019; S. 4117/H.R. 7777, the Paycheck Protection Small Business Forgiveness Act; H.R. 8265, To amend the Small Business Act and the CARES Act to establish a program for second draw loans and make other modifications to the paycheck protection program, and for other purposes; S. 4321, Continuing Small Business Recovery and Paycheck Protection Program Act; S. 4773, Continuing the Paycheck Protection Program Act; S. 4775, the Delivering Immediate Relief to America's Families, Schools and Small Businesses Act; H.R. 133, Consolidated Appropriations Act, 2021

Agencies Lobbied

Type of Issue

3rd Quarter, 2020

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 15, 2020. Original Filing: 301210148.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2020

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 20, 2020. Original Filing: 301196650.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2020

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 17, 2020. Original Filing: 301169356.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2019

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 21, 2020. Original Filing: 301124002.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2019

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 16, 2019. Original Filing: 301067087.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

S. 474, Stop the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act; H.R. 447 / S. 97, Affordable and Safe Prescription Drug Importation Act; S. 61 / H.R. 478, Safe and Affordable Drugs from Canada Act of 2019; S. 102 / H.R. 465, Prescription Drug Price Relief Act of 2019; H.R.1478, Affordable Insulin Act of 2019; S. 3, Keeping Health Insurance Affordable Act of 2019; H.R 965 / S. 340, CREATES Act of 2019; H.R. 1332, Fair Care Act of 2019; S. 637, CURE High Drug Prices Act; H.R. 1499, Protecting Consumer Access to Generic Drugs Act of 2019; S. 657, A bill to amend title XXVII of the Public Health Service Act to establish requirements with respect to prescription drug benefits; S. 709, Prescription Drug Pricing Dashboard Act; S. 977, Transparent Drug Pricing Act of 2019; S. 1895, Lower Health Care Costs Act; H.R. 2296, FAIR Drug Pricing Act of 2019; H.R. 3947, the Competition Prescription Act of 2019; H.R. 2279, the Safe Step Act; H.R. 3, the Lower Drug Costs Now Act of 2019; S. 2543, the Prescription Drug Pricing Reduction Act of 2019

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2019

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 18, 2019. Original Filing: 301048684.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2019

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 19, 2019. Original Filing: 301031234.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2018

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 22, 2019. Original Filing: 301013330.xml

Lobbying Issues

Implementation of Public Law 114-198 pharmacy provisions Implementation of Public Law 114-255 pharmacy provisions; H.R. 1854/S. 778, Prescription Drug Monitoring Act of 2017; S 892 / H.R. 4408, Opioid Addiction Prevention Act of 2017; HR 3528 / S.2460, Every Prescription Conveyed Securely Act; H.R. 3545, Overdose Prevention and Patient Safety Act; S. 1850, Protecting Jessica Grubbs Legacy Act; H.R. 1271, DXM Abuse Prevention Act of 2017; H.R. 1375, Prescriber Support Act of 2017; S. 523, Budgeting for Opioid Addiction Treatment Act; S. 581 / H.R. 5009, Jessies Law; S 1079, Protecting Americans from Dangerous Opioids Act; H.R. 4236, MONITOR Act of 2017; H.R. 3991, Expanded Access to Opioid Abuse Treatment Act of 2017; H.R. 4275, Empowering Pharmacists in the Fight Against Opioid Abuse Act; H.R. 5219, Opioid Prescription Verification Act of 2018; H.R. 5676, SENIOR Communities Protection Act of 2018; H.R. 5773, PASS Act of 2018; Draft legislation, Medicare Care Coordination Improvement Act of 2017; Draft legislation, Pain Care Coordination Act of 2018; S. 2456/H.R. 5311, CARA 2.0 Act of 2018; H.R. 5687, SOUND Disposal and Packaging Act; H.R. 5202, Ensuring Patient Access to Substance Use Disorder Treatments Act of 2018; H.R. 5812, CONNECTIONS Act; H.R. 5801, Medicaid PARTNERSHIP Act; H.R. 6, SUPPORT for Patients and Communities Act; H.R. 5808, Medicaid Pharmaceutical Home Act of 2018; H.R. 5675, To amend title XVIII of the Social Security Act to require prescription drug plan sponsors under the Medicare program to establish drug management programs for at-risk beneficiaries; S. 2680, Opioid Crisis Response Act of 2018; S. 2645 / H.R. 5628, Access to Increased Drug Disposal Act of 2018; H.R. 6600 / S. 3282, the DEA Order Clearinghouse Act of 2018; H.R. 6688, ALERT Act of 2018

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1316, Prescription Drug Price Transparency Act H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act; S. 413, Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 592, Pharmacy and Medically Underserved Areas Enhancement Act; S. 109, Pharmacy and Medically Underserved Areas Enhancement Act; H.R.1939 - To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes; S.637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; HR 394/ S 85, Restoring Access to Medication Act; HR 3921/S 1827, KIDS Act of 2017; HR 3271, Protecting Access to Diabetes Supplies Act of 2017; S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017; Centers for Medicare and Medicaid Services (CMS) Proposed Rule for the 2019 Medicare Part D Plan Year, pharmacy provisions; S.2553 / H.R. 6144, Know the Lowest Price Act of 2018; S.2554 / H.R. 6143, Patient Right to Know Drug Prices Act; H.R. 5343, Prescription Transparency Act of 2018; H.R. 5958, Phair Pricing Act of 2018; CMS Call Letter for 2019 Medicare Part D and Medicare Advantage Plans; H.R. 6733, Know the Cost Act of 2018; H.R. 6641, COST Act; H.R. 7339, Medicare for America Act of 2018; Proposed Rule, "Modernizing Part D and Medicare Advantage to Lower Drug Prices and Reduce Out-of-Pocket Expenses, CMS-4180-P"

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2018

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 17, 2018. Original Filing: 300987738.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2018

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 19, 2018. Original Filing: 300971252.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2018

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 13, 2018. Original Filing: 300944445.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1316, Prescription Drug Price Transparency Act H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act; S. 413, Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 592, Pharmacy and Medically Underserved Areas Enhancement Act; S. 109, Pharmacy and Medically Underserved Areas Enhancement Act; H.R.1939 - To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes; S.637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; HR 394/ S 85, Restoring Access to Medication Act; HR 3921/S 1827, KIDS Act of 2017; HR 3271, Protecting Access to Diabetes Supplies Act of 2017; S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017; Centers for Medicare and Medicaid Services (CMS) Proposed Rule for the 2019 Medicare Part D Plan Year, pharmacy provisions; S.2553, Know the Lowest Price Act of 2018; S.2554, Patient Right to Know Drug Prices Act; H.R. 5343, Prescription Transparency Act of 2018; Discussion draft, requiring plan sponsors to pass on revenue received from certain payments and adjustments to Medicare Part D enrollees; CMS Call Letter for 2019 Medicare Part D and Medicare Advantage Plans

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2017

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 19, 2018. Original Filing: 300927917.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R. 1316, Prescription Drug Price Transparency Act H.R. 1038, Improving Transparency and Accuracy in Medicare Part D Spending Act; S. 413, Improving Transparency and Accuracy in Medicare Part D Spending Act; H.R. 592, Pharmacy and Medically Underserved Areas Enhancement Act; S. 109, Pharmacy and Medically Underserved Areas Enhancement Act; H.R.1939 - To amend title XVIII of the Social Security Act to ensure equal access of Medicare beneficiaries to community pharmacies in underserved areas as network pharmacies under Medicare prescription drug coverage, and for other purposes; S.637 Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2017; HR 394/ S 85, Restoring Access to Medication Act; HR 3921/S 1827, KIDS Act of 2017; HR 3271, Protecting Access to Diabetes Supplies Act of 2017; S. 870, Creating High-Quality Results and Outcomes Necessary to Improve Chronic (CHRONIC) Care Act of 2017 Discussion draft, preventing cash price disclosure restrictions under Medicare prescription drug plan contracts with pharmacies; Centers for Medicare and Medicaid Services (CMS) Proposed Rule for the 2019 Medicare Part D Plan Year, pharmacy provisions; Electronic prior authorization (ePA) discussion draft

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2017

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 20, 2017. Original Filing: 300914190.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2017

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 20, 2017. Original Filing: 300892751.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2017

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 17, 2017. Original Filing: 300865958.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2016

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 18, 2017. Original Filing: 300848008.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2016

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 14, 2016. Original Filing: 300827718.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2016

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 20, 2016. Original Filing: 300819526.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2016

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 14, 2016. Original Filing: 300791466.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2015

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 14, 2016. Original Filing: 300772078.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2015

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 9, 2015. Original Filing: 300751679.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2015

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 27, 2015. Original Filing: 300747808.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2015

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 16, 2015. Original Filing: 300717509.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2014

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 20, 2015. Original Filing: 300702433.xml

Lobbying Issues

H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; S. 557 Medication Therapy Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; CMS proposed and final rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014; S.2862 - Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013; Generic Drug Pricing Spikes; The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013; H.R..3979 Carl Levin and Howard P. Buck Mckeon National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); Prescription Drug Abuse and Diversion; H.R. Res. 130-FY 2015 Continuing Resolution (though December 14, 2014); H.J. Res. 291- Making Further Continuing Appropriations for Fiscal Year 2015, And For Other Purposes (Until December 17, 2014); H.R.83 - FY2015 Omnibus; Consolidated and Further Continuing Appropriations Act; H.R. 4709 - Ensuring Patient Access and Effective Drug Enforcement Act of 2014;

Agencies Lobbied

Type of Issue

3rd Quarter, 2014

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 17, 2014. Original Filing: 300679155.xml

Lobbying Issues

H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; S. 557 Medication Therapy Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; CMS proposed and final rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014; S.2862 - Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013; Generic Drug Pricing Spikes; The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013; H.R..4435 National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); S. 2410 National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); Perscription Drug Abuse and Diversion; H.Con.Res 25: Establishing the budget for the United States government for Fiscal Year 2014 and setting forth appropriate budgetary levels for Fiscal Year 2015 through 2023; S.Con.Res 8: An original concurrent resolution setting forth the Congressional budget for the United States Government for Fiscal Year 2014, revising the appropriate budgetary levels for Fiscal year 2013, and setting forth the appropriate budgetary levels for Fiscal Years 2015 through 2023.

Agencies Lobbied

Type of Issue

2nd Quarter, 2014

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 16, 2014. Original Filing: 300658133.xml

Lobbying Issues

S.644- The Preventing Abuse of Cough Treatments of Acts of 2013; H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; H.R. 1188- The Preserving of Hometown Independent Pharmacies Act of 2013; CMS proposed rule on Medicare Part D; H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014; H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54; H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; S. 1493 - Medicare Efficient Drug Dispensing Act of 2013

Agencies Lobbied

Type of Issue

1st Quarter, 2014

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 15, 2014. Original Filing: 300636279.xml

Lobbying Issues

Fairness for Small Pharmacies in Part D Preferred Networks; Lifting Prohibition for Home Delivery of Diabetes Testing Supplies Home Delivery (H.R. 2845/S. 1935) ; S.644- The Preventing Abuse of Cough Treatments Act of 2013; H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; TRICARE Pharmacy Benefit/Provisions; Medicaid Reimbursement Cuts; PBM audit and generic pricing transparency and pricing reform; S. 867 - Medicare Prescription Drug Program Integrity and Transparency Act of 2013; CMS proposed rule on Medicare Part D; H.R. 4069 - Ensuring Patient Access and Effective Drug Enforcement Act of 2013; H.R. 4190 - To amend title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; FDAs action on and enforcement of Public Law No: 113-54.

Agencies Lobbied

Type of Issue

4th Quarter, 2013

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 15, 2014. Original Filing: 300615209.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION amended a lobbying report for in-house lobbying in Q32013 on Oct. 25, 2013 Original Filing: 300608528.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2013

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 10, 2013. Original Filing: 300592201.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2013

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 18, 2013. Original Filing: 300575939.xml

Lobbying Issues

H.R. 2375- Transparency and Accountability in Medicare Bidding Act of 2013; Fairness for Small Pharmacies in Preferred Networks; Repeal of National Mail Order Program for Diabetes Testing Supplies Home Delivery; S.644- The Preventing Abuse of Cough Treatments Act of 2013; H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; S.867- The Medicare Prescription Drug Program Integrity and Transparency Act of 2013;S.621- The Safe Prescribing Act of 2013; H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; S. 959, Pharmaceutical Compounding Quality and Accountability Act; S. 957- Drug Supply Chain Security Act; H.R.1919- Safeguarding America's Pharmaceuticals Act of 2013; Discussion House Draft Legislation on Compounded Drugs, Prescription Drug Diversion and Abuse; TRICARE Pharmacy Benefit/Provisions; Medicaid Reimbursment Cuts

Agencies Lobbied

Type of Issue

1st Quarter, 2013

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 9, 2013. Original Filing: 300548030.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2012

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 17, 2013. Original Filing: 300532400.xml

Lobbying Issues

S.1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; S. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; SEE ADDENDUMS. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S.319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in the National Defense Authorization Act for FY2013; Medicare Part B Revalidation; Hydrocodone Issues; S. 3376, PACT Act, S. 2467 and S. 3254 and H.R. 4310, he National Defense Authorization Act for FY2013; S. 3604, Improving Dementia Care Treatment for Older Adults Act of 2012; Deficit Reduction Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2012

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 16, 2012. Original Filing: 300507373.xml

Lobbying Issues

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; SEE ADDENDUMS. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; Hydrocodone Issues; S. 3376, PACT Act, S. 2467 and S. 3254 and H.R. 4310, the National Defense Authorization Act for Fiscal Year 2013; S. 3604, Improving Dementia Care Treatment for Older Adults Act of 2012;

Agencies Lobbied

Type of Issue

2nd Quarter, 2012

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 18, 2012. Original Filing: 300488772.xml

Lobbying Issues

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUMS. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation; S. 3376, PACT Act, Hydrocodone issues

Agencies Lobbied

Type of Issue

1st Quarter, 2012

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 19, 2012. Original Filing: 300467444.xml

Lobbying Issues

S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; SEE ADDENDUMS. 296, Preserving Access to Life-Savings Medications Act; Drug Cost Reduction Act; S. 2002 and H.R. 4095, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; H.R. 4215, The Medicare Pharmacy Transparency and Fair Auditing Act; Prescription Drug User Fee Act; Pharmaceutical Supply Chain Security; Drug Shortages legislation; Prescription drug diversion and abuse; TRICARE Pharmacy Benefit/Provisions for inclusion in National Defense Authorization Act for FY2013; Medicare Part B Revalidation

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION amended a lobbying report for in-house lobbying in Q42011 on Jan. 23, 2015 Original Filing: 300709369.xml

Lobbying Issues

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939 Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years; S. 1356 Affordable Medicines Utilization Act of 2011; S. 296 Preserving Access to Life-Savings Medications Act of 200; S 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S.1251, Medicare and Medicare FAST Act; S. 882 STOP Act; S. 319 Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

Agencies Lobbied

Type of Issue

4th Quarter, 2011

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 19, 2012. Original Filing: 300443360.xml

Lobbying Issues

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; SEE ADDENDUMH.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011; H.R. 1936, the Medicare Access to Diabetes Act of 2011; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011; HR. 1409, the Quality Health Care Coalition Act of 2011; H.R. 1839, the Community Pharmacy Fairness Act; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; H.R. 2939, Pharmaceutical Stewardship Act of 2011; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011; S. 1356, Affordable Medicines Utilization Act of 2011; S. 296, Preserving Access to Life-Savings Medications Act; H.R. 2245, Preserving Access to Life-Savings; Medications Act of 2011; S. 1699, Prescription Drug Cost Reduction Act; S. 1867, National Defense Authorization Act for 2012; S. 2002, Online Pharmacy Safety Act; S. 1251, Medicare and Medicaid FAST Act; S. 882, STOP Act; S. 319, Pharmaceutical Market Access and Drug Safety Act of 2011; S. 1002, SAFE Doses Act; The Joint Select Committee on Deficit Reduction

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2011

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 17, 2011. Original Filing: 300415720.xml

Lobbying Issues

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION amended a lobbying report for in-house lobbying in Q22011 on Jan. 23, 2015 Original Filing: 300709364.xml

Lobbying Issues

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years. S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION amended a lobbying report for in-house lobbying in Q22011 on Dec. 12, 2011 Original Filing: 300433525.xml

Lobbying Issues

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform oversight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharmacies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption, which would allow groups of independent pharmacies to negotiate PBM contracts; S. 1560, Nursing Home Resident Pain Relief Act of 2011; S. 1699, a bill to reduce the costs of prescription drugs under the Medicare program, and for other purposes; Worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 3408 drug program as well as educating staff on the current 340b program; Sought Congressional support for the FTC investigation of the merger between two major national PBMs; H.R. 1540 and S. 1253, the National Defense Authorization Act for FY 12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; NCPA Submits Statement for Senate Committee Hearing on Drug Supply Safety. The U.S. Senate Health, Education, Labor and Pensions (HELP) Committee held a hearing this week on Securing the Pharmaceutical Supply Chain.; NCPA sent a letter to the Special Congressional Committee charged with finding $1.2 trillion in Federal program savings, outlining our proposals to reduce costs while preserving patient choice and access to community pharmacy; NCPA Submits Statement on Drug Shortages Hearing. NCPA submitted a statement outlining our concerns as the FDA and private sector continue to work on resolving the drug shortages issue; Pharmaceutical Stewardship Act of 2011 (H.R. 2939), to provide for the disposal of drugs pursuant to national pharmaceutical stewardship programs; H.R. 866, the National All Schedules Prescription Electronic Reporting Act (NASPER) Reauthorization Act of 2011, that would again reauthorize NASPER for 3 additional years.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2011

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 22, 2011. Original Filing: 300406705.xml

Lobbying Issues

H.R. 979, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2011, legislation to reform ovesight authority for OPM for the FEHBP drug benefit; H.R. 891 and S. 274, the Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, the Fairness in Medicare Bidding Act, this legislation would repeal the competitive bidding program, in the Medicare Part B durable medical equipment, prosthetics, orthotics and supplies (DMEPOS) program; S. 1058 and H.R. 1971, the Pharmacy Competition and Consumer Choice Act of 2011, this legislation expands transparency requirements for PBMs and limits certain audit practices by PBMs; H.R. 1936, the Medicare Access to Diabetes Act of 2011, legislation exempts small pharmacies from the DME competitive bidding program for diabetes test supplies; H.R. 1946, the Preserving Our Hometown Independent Pharmacies Act of 2011, would provide a narrow anti-trust exemption to allow small pharamcies to form pools to negotiate with PBMs; HR. 1409, the Quality Health Care Coalition Act of 2011, legislation would exempt health care professionals from federal antitrust laws for the purposes of contract negotiations with health plans; H.R. 1839, the Community Pharmacy Fairness Act, legislation would provide a narrow anti-trust exemption which would allow groups of independent pharmacies to negotiate PBM contracts; continue to work with Senate Aging Committee om legislation addressing the role of nurses as agents of prescribers in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study being conducted on the 340B drug program as well as educating staff on the current 340b program; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national PBM; H.R. 1540 and S. 1253 , the National Defense Authorization Act for FY12, includes funding for the TRICARE pharmacy program; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids from Dangerous Drugs Act of 2011; submitted comments for an E&C Subcommittee on Commerce, Manufacturing, and Trade hearing called The Warning: The Growing Danger of Prescription Drug Diversion."

Agencies Lobbied

Type of Issue

Lobbying Issues

H.R.4, the Comprehensive 1099 Taxpayer Protection and Repayment of Exchange Subsidy Overpayments Act of 2011, legislation would repeal provision of the Patient Protection and Affordable Care Act (PPACA) that expanded 1099 tax reporting requirements for businesses that purchase goods and services of more than $600-became law 4/14/11; opposed Senate amendment 392 to S. 782 which would delay implementation of the of new caps on credit card fees.S. 312 and H.R. 605, the Patients' Freedom to Choose Act, which would repeal the provision in the 2010 health care law that prohibits individuals from using funds from either Health Savings Accounts (HSAs) or Flexible Spending Accounts (FSAs) to purchase over-the-counter medication without a prescription.

Agencies Lobbied

Type of Issue

1st Quarter, 2011

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 25, 2011. Original Filing: 300381505.xml

Lobbying Issues

H.R. 979, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2011, legislation to reform the oversight authority for OPM for FEHBP drug benefit; H.R. 891 and S. 274, Medication Therapy Management Benefits Act of 2011, which would expand beneficiary access to MTM services under Part D; H.R. 1041, Fairness in Medicare Bidding Act , this legislation would repeal the competitive bidding program in the Medicare Part B durable medical equipment prosthetics, orthotics and supplies (DMEPOS) program; worked with House and Senate Members on Congressional letter to CMS regarding the pending rule which was to be published on the new short cycle requirements for long-term care prescription dispensing; continue to work with Senate Committee on Aging on potential legislation addressing the role of nurses as agents in long-term care facilities; worked with Senate Finance and House Energy and Commerce staff on addressing questions raised by GAO regarding a study they are conducting on the 340B drug program which was mandated by Congress; FY12 National Defense Authorization Act, includes funding for for the TRICARE pharmacy program (bill not yet introduced); H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions relating to pedigree and track and trace-no bill introduced in the current Congress; H.R. 5234, the PBM Audit Reform ad Transparency Act of 2010 (111th Congress), no bill introduced in this Congress; H.R. 5235, Medicare Access to Diabetes Supplies Act (111th Congress), no bill introduced in this Congress; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a major national pharmacy benefit manager (PBM); submitted comments to House Energy and Commerce Committee for a hearing on the impact of health care reform on providers; submitted comments to House Committee on Oversight and Government Reform regarding the impact of certain regulations on small business pharmacies; H.R. 1316, the Pill Mill Crackdown Act of 2011; S. 507, Prescription Drug Abuse Prevention and Treatment Act of 2011; S. 513, Saving Kids From Dangerous Drugs Act of 2011.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2010

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 20, 2011. Original Filing: 300349288.xml

Lobbying Issues

H.R. 4489, the FEHBP Prescription Integrity, Transparency and Cost Savings Act of 2010; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; working with Senate Committee on Health, Education, Labor and Pensions on a potential hearing; working with House Committee on Energy and Commerce (health subcommittee) on a potential hearing; H.R. 5235, the Medicare Access to Diabetes Supplies Act of 2010 and working on Senate companion; H.R. 4853, the Tax ReRelief and Job Creation Act of 2010-worked to get provisions related to Part B DME competitive bidding program included in the legislation; H.R. 6523, the National Defense Authoirzation Act for 2011, includes funding for the Department of Defense and covers the TRICARE pharmacy program; worked with Senate offices to gain support for the implementation of an authorized grant program for MTM services; worked with Senate Aging Committee on the issues of nurses-as-agents in long term care facilities and submitted questions for the nomination hearing of Drug Enforcement Agency Acting Administrator Michele Leonhart; worked with Congressional offices on the issue of Medicare Part B recoupment by CMS; sought Congressional support for the FTC investigation of the merger of between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); worked with Congressional offices seeking clarification from the Department of Treasury regarding the new "over the counter" rules with Flexible Spending Accounts (FSA).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2010

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 18, 2010. Original Filing: 300315409.xml

Lobbying Issues

H.R. 1204, the Community Pharmacy Fairness Act of 2009; H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2010 and working on Senate companion; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; working with Senate Committee on Health, Education, Labor and pensions on a potential hearing; working with House Committee on Energy and Commerce (health subcommittee) on a potential hearing; worked with the Senate Committee on Aging to provide information for an ongoing committee investigation of certain retail pharmacy practices; H.R. 5235, the Medicare Access to Diabetes Supplies Act of 2010 and working on Senate companion; H.R. 3790, legislation to eliminate the Medicare Part B DME competitive bidding program; submitted statement for the House Committee on Energy and Commerce hearing on the Part B DME competitive bidding program; H.R. 1586, the Education Jobs and Medicaid funding bill, which included an extension of FMAP and change to the AMP definition and became law on 8/10/2010; H.R. 5136 and S. 3454, the FY11 National Defense Authorization Act, includes funding for the Department of Defense and covers the TRICARE pharmacy program; H.R. 3108 and S. 1383, the Medication Therapy Management (MTM) Expanded Benefit Act; worked with Senate offices to gain support for the implemenation of an authpirzed grant program for MTM services; worked with Senate Aging Committee on the issue of nurses as agents in long-term care facilties; H.R. 5710, National All Schedules Prescription Electronic Reporting Reauthorization Act of 2010 (NASPER); H.R. 5809, the Safe Drug Disposal Act and S. 3397, the Secure & Responsible Drug Disposal Act (became law 10-12-10); worked with Congressional offices on the issue of Medicare Part B recoupment by CMS; sough Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); worked with Congressional offices in seeking clarification from the Department of Treasury regarding the new "over the counter" rules with Flexible Spending Accounts (FSA).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION amended a lobbying report for in-house lobbying in Q22010 on Nov. 8, 2011 Original Filing: 300432202.xml

Lobbying Issues

H.R. 1204, the Community Pharmacy Fairness Act of 2009 and S. 2191, the Community Pharmacy Fairness Act from the 110th Congress; H.R. 4489, the FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act of 2010 and working on Senate companion; H.R. 5234, the PBM Audit Reform and Transparency Act of 2010 and working on Senate companion; H.R. 6331 (110th Congress), the Medicare Improvement for Patients and Providers Act of 2008-Sec. 172 related to the implementation of theMedciare Part D prompt pay requirements and submission of claims by pharmacies located in or contracting with long-term care facilities; H.R. 5235, the Medicare Access to Diabetic Supplies Act of 2010 and working on Senate companion; H.R. 3790, legislation to eliminate the Medicare Part B DME competitive bidding program; H.R. 4213, the American Jobs and Closing Tax Loopholes Act of 2010-advocated for inclusion of the extension of the Federal Medicaid Matching Rate (FMAP) and limiting access to 340b drugs in outpatient settings to only eligible individuals in both House bill and Senate amendment; H.R. 5839 (110th Congress) the Safeguarding America's Pharmaceuticals Act of 2008, provisions related to pedigree and track and trace requirements-no bill introduced in the current Congress; H.R. 5136 and S. 3454, the FY11 National Defense Authorization Act , includes funding for the Department of Defense FY11 budget and covers the TRICARE pharmacy program; H.R. 3108 and S. 3543, the Medication Therapy Management Expanded Benefit Act; H.R. 2923, the Combat Meth Act of 2009; S. 1383, the Dextromethorphan Abuse Reduction Act of 2009; submitted comments to Senate Committee on Aging on prescription drug disposal and the role of nurses as agents in long-term care facilities; sought Congressional support to stop exclusion of certain retail pharmacies from "employee prescription drug plans;" worked with Congressional offices to request the FTC review the 180 day generic drug marketing exclusivity policies of certain generic manufacturers; sought Congressional support for the FTC investigation of the merger between a major retail pharmacy chain and a national pharmacy benefit manager (PBM); submitted comments to Senate Judiciary Committee regarding the FTC and DOJ antitrust oversight; submitted comments to Senate Homeland Security and Government Affairs Committee regarding a HHS OIG report, "Invalid Prescriber Identifiers on Medicare Part D Drug Claims;" FSA debit card program-seeking Congressional support to amend IRS guidance (no legislation).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

2nd Quarter, 2010

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 20, 2010. Original Filing: 300300067.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

1st Quarter, 2010

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 19, 2010. Original Filing: 300263259.xml

Lobbying Issues

H.R. 1204, the "Community Pharmacy Fairness Act of 2009", and S. 2161 Community Pharmacy Fairness Act from the 110th Congress; H.R. 616 and S. 511, the "Access to Durable Medical Equipment Act of 2009"; H.R. 1970 and S. 956, the "Preserve Patient Access to Reputable DMEPOS Providers Act of 2009"; H.R. 6331 (110th Congress), the "Medicare Improvements for Patients and Providers Act of 2008." Sec. 154 related to Medicare DMEPOS competitive acquisition program; and Sec. 172, related tosubmission of claims by pharmacies located in or contracting with long-term care facilities; Sec. 203, related to pharmacy payment under Medicaid; H.R. 1, "American Recovery and Reinvestment Act - P.L. 111-5 -- provisions related to Health Information Technology and HIPPA requirements; H.R. 5839 of the 110th Congress, the "Safeguarding America's Pharmaceuticals Act of 2008", provision relating to pedigree and track and trace requirements; H.R. 1427, the "Promoting Innovation and Life Savings Medicines Act of 2009"; H.R. 2647 and S. 1390, National Defense Authorization Act for 2010-Provides for the funding for the Department of Defense for fiscal year 2010-including the Tricare pharmacy program; H.R. 3108, the "Medication Therapy Benefits Act of 2009"; S. 1649, the "Weapons of Mass Destruction (WMD) Prevention and Preparednesss Act of 2009, pharmacy provider provisions; S. 1383, the "Dextromethorphan Abuse Reduction Act; H.R.3663: To amend title XVIII of the Social Security Act to delay the date on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies; H.R. 2891, the "Access to Frontline Health Care Act of 2009"; H.R. 3200, the "America's Affordable Health Choices Act of 2009"; the draft Senate HELP Committee's "Affordable Health Choices Act of 2009"; Senate Finance Committee draft health care reform bill, all provisions related to Medicaid AMP pharmacy reimbursement, Medicare Part B DMEPOS accreditation and surety bond requirements, medication therapy management, public plan option and pharmacy benefit manager transparency requirements; H.R.3590: An act entitled The Patient Protection and Affordable Care ActDME Accreditation, AMP Fix, PBM Transparency, MTM Expansion, OPM PBA v. PBM; Senator Akaka Amendment to Senate version of H.R. 3590 to establish automatic enrollment into a Medicare Part D "chronic care management" program for targeted individuals; Senator Brown amendment to H.R. 3590 eliminating DMEPOS surety bond requirement for retail pharmacies; Senator Dorgan Drug Reimportation amendment to H.R. 3590; FSA Debit Card Programseeking Congressional support to amend IRS guidance (no legislation). P.L. 110-275, the Medicare Improvements for Patients and Providers Act of 2008, implementation of Part D prompt payment and Part B DMEPOS provisions; H.R. 4213, American Workers, State, and Business Relief Act of 2010, section 213, Medicare Part B DMEPOS accreditation requirements; H.R. 4872 and substitute amendment to H.R. 4872, the Health Care and Education Affordability Reconciliation Act of 2010, section 1101, the Medicare Part D "donut hole", section 1305, oversight of DMEPOS suppliers.

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2009

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Jan. 20, 2010. Original Filing: 300240869.xml

Lobbying Issues

H.R. 1204, the "Community Pharmacy Fairness Act of 2009", and S. 2161 Community Pharmacy Fairness Act from the 110th Congress; H.R. 616 and S. 511, the "Access to Durable Medical Equipment Act of 2009"; H.R. 1970 and S. 956, the "Preserve Patient Access to Reputable DMEPOS Providers Act of 2009"; H.R. 6331 (110th Congress), the "Medicare Improvements for Patients and Providers Act of 2008." Sec. 154 related to Medicare DMEPOS competitive acquisition program; and Sec. 172, related tosubmission of claims by pharmacies located in or contracting with long-term care facilities; Sec. 203, related to pharmacy payment under Medicaid; H.R. 1, "American Recovery and Reinvestment Act - P.L. 111-5 -- provisions related to Health Information Technology and HIPPA requirements; H.R. 5839 of the 110th Congress, the "Safeguarding America's Pharmaceuticals Act of 2008", provision relating to pedigree and track and trace requirements; H.R. 1427, the "Promoting Innovation and Life Savings Medicines Act of 2009"; H.R. 2647 and S. 1390, National Defense Authorization Act for 2010-Provides for the funding for the Department of Defense for fiscal year 2010-including the Tricare pharmacy program; H.R. 3108, the "Medication Therapy Benefits Act of 2009"; S. 1649, the "Weapons of Mass Destruction (WMD) Prevention and Preparednesss Act of 2009, pharmacy provider provisions; S. 1383, the "Dextromethorphan Abuse Reduction Act; H.R.3763: To amend the Fair Credit Reporting Act to provide for an exclusion from Red Flag Guidelines for certain businesses, pharmacy provision; H.R.3663: To amend title XVIII of the Social Security Act to delay the date on which the accreditation requirement under the Medicare Program applies to suppliers of durable medical equipment that are pharmacies; H.R. 2891, the "Access to Frontline Health Care Act of 2009"; H.R. 3200, the "America's Affordable Health Choices Act of 2009"; the draft Senate HELP Committee's "Affordable Health Choices Act of 2009"; Senate Finance Committee draft health care reform bill, all provisions related to Medicaid AMP pharmacy reimbursement, Medicare Part B DMEPOS accreditation and surety bond requirements, medication therapy management, public plan option and pharmacy benefit manager transparency requirements; H.R.3590: An act entitled The Patient Protection and Affordable Care ActDME Accreditation, AMP Fix, PBM Transparency, MTM Expansion, OPM PBA v. PBM; Senator Akaka Amendment to Senate version of H.R. 3590 to establish automatic enrollment into a Medicare Part D "chronic care management" program for targeted individuals; Senator Brown amendment to H.R. 3590 eliminating DMEPOS surety bond requirement for retail pharmacies; Senator Dorgan Drug Reimportation amendment to H.R. 3590; FSA Debit Card Programseeking Congressional support to amend IRS guidance (no legislation).

Agencies Lobbied

Type of Issue

Lobbying Issues

Agencies Lobbied

Type of Issue

3rd Quarter, 2009

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 16, 2009. Original Filing: 300207962.xml

Lobbying Issues

H.R. 1204, the "Community Pharmacy Fairness Act of 2009", and S. 2161 Community Pharmacy Fairness Act from the 100th Congress; H.R. 616 and S. 511, the "Access to Durable Medical Equipment Act of 2009"; H.R. 1970 and S. 956, the "Preserve Patient Access to Reputable DMEPOS Providers Act of 2009"; H.R. 6331 (110th Congress), the "Medicare Improvements for Patients and Providers Act of 2008." Sec. 154 related to Medicare DMEPOS competitive acquisition program; (more)Sec. 203, related to pharmacy payment under Medicaid; H.R. 1, "American Recovery and Reinvestment Act - P.L. 111-5 -- provisions related to Health Information Technology and HIPPA requirements and small business tax provisions; H.R. 1166 (E-Fencing Enforcement Act of 2009), H.R. 1173 (Organized Retail Crime Act of 2009) and S. 470 (Combating Organized Retail Crime Act of 2009); H.R. 5839 of the 110th Congress, the "Safeguarding America's Pharmaceuticals Act of 2008", provision relating to pedigree and track and trace requirements; H.R. 1427, the "Promoting Innovation and Life Savings Medicines Act of 2009"; H.R. 2647 and S. 1390, National Defense Authorization Act for 2010-Provides for the funding for the Department of Defense for fiscal year 2010-including the Tricare pharmacy program; H.R. 3108, the "Medication Therapy Benefits Act of 2009"; S. 1649, the "Weapons of Mass Destruction (WMD) Prevention and Preparednesss Act of 2009; S. 1383, the "Dextromethorphan Abuse Reduction Act; and "H.R. 2891, the "Access to Frontline Health Care Act of 2009"; H.R. 3200, the "America's Affordable Health Choices Act of 2009"; the draft Senate HELP Committee's "Affordable Health Choices Act of 2009"; Senate Finance Committee draft health care reform bill, all provisions related to Medicaid AMP pharmacy reimbursement, Medicare Part B DMEPOS accreditation and surety bond requirements, medication therapy management, public plan option and requirements for businesses to provide health insurance, and pharmacy benefit manager transparency requirements.

Agencies Lobbied

Type of Issue

2nd Quarter, 2009

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 20, 2009. Original Filing: 300191103.xml

Lobbying Issues

H.R. 1204, the "Community Pharmacy Fairness Act of 2009", and S. 2161 Community Pharmacy Fairness Act from the 100th Congress; H.R. 616 and S. 511, the "Access to Durable Medical Equipment Act of 2009"; H.R. 1970 and S. 956, the "Preserve Patient Access to Reputable DMEPOS Providers Act of 2009"; H.R. 6331 (110th Congress), the "Medicare Improvements for Patients and Providers Act of 2008." Sec. 154 related to Medicare DMEPOS competitive acquisition program; (more)Sec. 203, related to pharmacy payment under Medicaid; H.R. 1, "American Recovery and Reinvestment Act - P.L. 111-5 -- provisions related to Health Information Technology and HIPPA requirements and small business tax provisions; H.R. 1166 (E-Fencing Enforcement Act of 2009), H.R. 1173 (Organized Retail Crime Act of 2009) and S. 470 (Combating Organized Retail Crime Act of 2009); H.R. 5839 of the 110th Congress, the "Safeguarding America's Pharmaceuticals Act of 2008", provision relating to pedigree and track and trace requirements; H.R. 1427, the "Promoting Innovation and Life savings Medicines Act of 2009"; H.R. 3202, the "Water Protection and Reinvestment Act of 2009"; H.R.2647 and S. 1390, National Defense Authorization Act for 2010-Provides for the funding for the Department of Defense for fiscal year 2010-including the Tricare pharmacy program; H.R. 3108, the "Medication Therpay Benefits Act of 2009"; and "H.R. 2891, the "Access to Frontline Health Care Act of 2009"; H.R. 3200, the "America's Affordable Health Choices Act of 2009"; the draft Senate HELP Committee's "Affordable Health Choices Act of 2009"; the yet-to-be-released draft Senate Finance Committee draft health care reform bill, all provisions related to Medicaid AMP pharmacy reimbursement, Medicare Part B DMEPOS accreditation and surety bond requirements, public plan option and requirements for businesses to provide health insurance.

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Amendment

NATIONAL COMMUNITY PHARMACISTS ASSOCIATION amended a lobbying report for in-house lobbying in Q12009 on Aug. 11, 2009 Original Filing: 300197049.xml

Lobbying Issues

H.R. 1204, the "Community Pharmacy Fairness Act of 2009"; H.R. 616 and S. 511, the "Access to Durable Medical Equipment Act of 2009"; H.R. 1970, the "Preserve Patient Access to Reputable DMEPOS Providers Act of 2009"; Potential revisions to HR 5839 of the 110th Congress, the "Safeguarding America's Pharmaceuticals Act of 2008," provisions relating to pedigree and track and trace requirements; HR 6331 (110th Congress), the "Medicare Improvements for Patients and Providers Act of 2008," Sec. 154 related to Medicare DMEPOS competitive acquisition program, Sec. 203, related to pharmacy reimbursement under Medicaid; FY 2010 DOD reauthorization bill; TRICARE provisions; H.R. 1, "American Recovery and Reinvestment Act - P.L. 111-5 -- provisions related to Health Information Technology and HIPPA requirements and small business tax provisions; H.R. 1166, H.R. 1173 and S. 470 addressing organized retail crime; possible reintroduction of S. 1951and H.R. 3700 of the 110th Congress, the "Fair Medicaid Drug Payment Act of 2007."

Agencies Lobbied

Type of Issue

1st Quarter, 2009

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 20, 2009. Original Filing: 300161252.xml

Lobbying Issues

Agencies Lobbied

Type of Issue

4th Quarter, 2008

Q4 Report

In Q4, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Feb. 3, 2009. Original Filing: 300136594.xml

Lobbying Issues

HR 971, the "Community Pharmacy Fairness Act of 2007"; S. 2161, the "Community Pharmacy Fairness Act of 2007"; HR 2900, provision related to pedigree requirements; HR 4 and S.3, the "Medicare Prescription Drug Price Negotiation Act of 2007"; HR 1474, the "Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007; potential legislation related to Medicare DMEPOS accreditation and surety bond requirements; Sec. 913 of FDAAA of 2007, relating to development of a standard numerical drug identifier; HR 5839, the "Safeguarding America's Pharmaceuticals Act of 2008," provisions relating to pedigree and track and trace requirements; HR 6852, the "Small Business Cooperative for Health Care Options to Improve Coverage for Employees (CHOICE) Act of 2008; potential amendments to S. 1693, the "Wired for Health Care Quality Act," re privacy issues; S. 980, the "Ryan Haight Online Pharmacy Consumer Protection Act of 2008"; HR 3140, "Saving Our Community Pharmacies Act of 2007"; S. 1951, the "Fair Medicaid Drug Payment Act of 2007"; S. 1954, the "Pharmacy Access Improvement (PhAIm) Act of 2007"; HR 3700, the "Fair Medicaid Drug Payment Act of 2007"; HR 6357, the "PRO(TECH)T Act of 2008", provisions impacting health technology requirements for pharmacies; HR 6331, the "Medicare Improvements for Patients and Providers Act of 2008," Sec. 154 related to Medicare DMEPOS competitive acquisition program, Sec. 171 related to prompt payment of Part D reimbursements to pharmacies, Sec. 203, related to pharmacy reimbursement under Medicaid.

Agencies Lobbied

Type of Issue

3rd Quarter, 2008

Q3 Report

In Q3, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on Oct. 20, 2008. Original Filing: 300102510.xml

Lobbying Issues

I. HR 971, the "Community Pharmacy Fairness Act of 2007"; S. 2161, the "Community Pharmacy Fairness Act of 2007"; CMS-2238-P, CMS-2238-FC and CMS-2238-IFC, the proposed, final rule, and interim final rule re implementation the Medicaid provisions of the Deficit Reduction Act of 2005;CMS-1270F, Final rule implementing the competitive acquisition program requirements for Durable Medical Equipment Prosthetics, Orthotics and Supplies; HR 2900, provision related to pedigree requirements; HR 4 and S.3, the "Medicare Prescription Drug Price Negotiation Act of 2007"; potential language not included in S. 2499, the "Medicare, Medicaid and SCHIP Extension Act of 2007" re e-prescribing; HR 1474, the "Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007; Sec. 913 of FDAAA of 2007, relating to development of a standard numerical drug identifier; and HR 5839, the "Safeguarding America's Pharmaceuticals Act of 2008," provisions relating to imposition of pedigree and track and trace requirements upon community pharmacy; HR 6852, the "Small Business Cooperative for Health Care Options to Improve Coverage for Employees (CHOICE) Act of 2008; S. 1693, the "Wired for Health Care Quality Act," particularly Sec. 401; S. 980, the "Ryan Haight Online Pharmacy Consumer Protection Act of 2008"; II. and also HR 3140, "Saving Our Community Pharmacies Act of 2007"; S. 1951, the "Fair Medicaid Drug Payment Act of 2007"; S. 1954, the "Pharmacy Access Improvement (PhAIm) Act of 2007"; HR 3700, the "Fair Medicaid Drug Payment Act of 2007"; Sec. 7002(b) of HR 2006 and PL 110-28, "Requirements for Use of Tamper-Resistant Prescription Pads Under the Medicaid Program", (the U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act of 2007); PL 110-181 -- HR 1585, HR 4986 and S. 1547, National Defense Authorization Act for Fiscal Year 2008, provisions related to pharmacy payment - sections 703 and 702 of HR 1585 and HR 4986 and Sec. 701 of S. 1547, HR 6357, the "PRO(TECH)T Act of 2008", provisions impacting health technology requirements for pharmacies; HR 6331, the "Medicare Improvements for Patients and Providers Act of 2008," Sec. 154 related to Medicare DMEPOS competitive acquisition program, Sec. 171 related to prompt payment of Part D reimbursements to pharmacies, Sec. 203, related to pharmacy reimbursement under Medicaid, all of II. done separately and as joint project with the National Association of Chain Drug Stores for the Coalition for Community Pharmacy Action.

Agencies Lobbied

Type of Issue

2nd Quarter, 2008

Q2 Report

In Q2, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on July 17, 2008. Original Filing: 300070585.xml

Lobbying Issues

I. HR 971, the "Community Pharmacy Fairness Act of 2007"; S. 2161, the "Community Pharmacy Fairness Act of 2007"; CMS-2238-P, CMS-2238-FC and CMS-2238-IFC, the proposed, final rule, and interim final rule re implementation the Medicaid provisions of the Deficit Reduction Act of 2005;CMS-1270F, Final rule implementing the competitive acquisition program requirements for Durable Medical Equipment Prosthetics, Orthotics and Supplies; HR 2900, provision related to pedigree requirements; HR 4 and S.3, the "Medicare Prescription Drug Price Negotiation Act of 2007"; potential language not included in S. 2499, the "Medicare, Medicaid and SCHIP Extension Act of 2007" re e-prescribing; HR 1474, the "Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007; CMS-6006-P, proposed rule requring a surety bond for all Medicare DMEPOS providers; Sec. 913 of FDAAA of 2007, relating to development of a standard numerical drug identifier; and HR 5839, the "Safeguarding America's Pharmaceuticals Act of 2008," provisions relating to imposition of pedigree and track and trace requirements upon community pharmacy; II. and also HR 3140, "Saving Our Community Pharmacies Act of 2007"; S. 1951, the "Fair Medicaid Drug Payment Act of 2007"; S. 1954, the "Pharmacy Access Improvement (PhAIm) Act of 2007"; HR 3700, the "Fair Medicaid Drug Payment Act of 2007"; Sec. 7002(b) of HR 2006 and PL 110-28, "Requirements for Use of Tamper-Resistant Prescription Pads Under the Medicaid Program", (the U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act of 2007); PL 110-181 -- HR 1585, HR 4986 and S. 1547, National Defense Authorization Act for Fiscal Year 2008, provisions related to pharmacy payment - sections 703 and 702 of HR 1585 and HR 4986 and Sec. 701 of S. 1547, HR 6357, the "PRO(TECH)T Act of 2008", provisions impacting health technology requirements for pharmacies; HR 6331, the "Medicare Improvements for Patients and Prviders Act of 2008," Sec. 154 related to Medicare DMEPOS competitive acquisition program, Sec. 171 related to prompt payment of Part D reimbursements to pharmacies, Sec. 203, related to pharmacy reimbursement under Medicaid, all of II. done separately and as joint project with the National Association of Chain Drug Stores for the Coalition for Community Pharmacy Action.

Agencies Lobbied

Type of Issue

1st Quarter, 2008

Q1 Report

In Q1, NATIONAL COMMUNITY PHARMACISTS ASSOCIATION had in-house lobbyists. The report was filed on April 16, 2008. Original Filing: 300038078.xml

Lobbying Issues

I. HR 971, the "Community Pharmacy Fairness Act of 2007"; S. 2161, the "Community Pharmacy Fairness Act of 2007"; CMS-2238-P, CMS-2238-FC and CMS-2238-IFC, the proposed, final rule, and interim final rule re implementation the Medicaid provisions of the Deficit Reduction Act of 2005;CMS-1270F, Final rule implementing the competitive acquisition program requirements for Durable Medical Equipment Prosthetics, Orthotics and Supplies; HR 2900, provision related to pedigree requirements; HR 4 and S.3, the "Medicare Prescription Drug Price Negotiation Act of 2007"; potential language not included in S. 2499, the "Medicare, Medicaid and SCHIP Extension Act of 2007" re e-prescribing; HR 1474, the "Fair and Speedy Treatment (FAST) of Medicare Prescription Drug Claims Act of 2007; CMS-6006-P, proposed rule requring a surety bond for all Medicare DMEPOS providers; Sec. 913 of FDAAA of 2007, relating to development of a standard numerical drug identifier; II. and also HR 3140, "Saving Our Community Pharmacies Act of 2007"; S. 1951, the "Fair Medicaid Drug Payment Act of 2007"; S. 1954, the "Pharmacy Access Improvement (PhAIm) Act of 2007"; HR 3700, the "Fair Medicaid Drug Payment Act of 2007"; Sec. 7002(b) of HR 2006 and PL 110-28, "Requirements for Use of Tamper-Resistant Prescription Pads Under the Medicaid Program", (the U.S. Troop Readiness, Veterans' Care, Katrina Recovery, and Iraq Accountability Appropriations Act of 2007); PL 110-181 -- HR 1585, HR 4986 and S. 1547, National Defense Authorization Act for Fiscal Year 2008, provisions related to pharmacy payment - sections 703 and 702 of HR 1585 and HR 4986 and Sec. 701 of S. 1547, all of II. done separately and as joint project with the National Association of Chain Drug Stores for the Coalition for Community Pharmacy Action.

Agencies Lobbied

Type of Issue

Source: Clerk of the U.S. House of Representatives and Secretary of the Senate

Legislators

Bills

Statements

Lobbying

Travel

Lobbyists

Disclosures Filed